header logo image


Page 697«..1020..696697698699..710720..»

Malcolm McGregor, 5, who is fighting cancer, returns home to hero’s welcome – Wisconsin Rapids Tribune

February 4th, 2020 12:50 pm

Malcolm McGregor, 5, has been receiving treatment in Madison for neuroblastoma and returned home Sunday for the first time in four months. 24/7 Wall Street

GRAND RAPIDS Malcolm McGregor returned home to a heros welcome Sunday.

Family and friends erupted into cheers as the 5-year-old boy pulled into his driveway for the first time in four months.The McGregor family was escorted through Kellner and back to their Grand Rapids home by emergency vehicles from the Grand Rapids Police Department, Grand Rapids Fire Department, Wood County Sheriffs Department, Wood County Sheriff's Rescue, United Ambulance and others.

Groups of well-wishers also gathered along 80th Street in Kellner to welcome him home.

Malcolm, who has been battling stage 4 high-risk neuroblastoma since Dec. 24, 2018, spent the past four months at American Family Children's Hospitaland the Ronald McDonald House in Madison after receiving his second stem cell transplant in early October. The stay was initially expected to last only four weeks, but fevers, high blood pressure, infections and other life-threatening complications extended his stay.

RELATED:4-year-old Wisconsin Rapids boy fights cancer; family asks for cards and letters

RELATED:Wisconsin Rapids' 2019 People of the Year

Autoplay

Show Thumbnails

Show Captions

His parents, Jon and Tracy McGregor, have provided near-daily updates on Malcolms health struggles and victories during the stay on the Facebook group Malcolms MARVELous SUPER HERO cancer fighters, and on Saturday morningthey shared the happy news.

Four months Malcolm has been here. He missed four holidays. He almost died. Just thinking of writing this post has me all kinds of emotional but here we go. MALCOLM IS GOING HOME! Tracy McGregor wrote.

The McGregor family first shared Malcolms story with a Wisconsin Rapids Daily Tribune reporter in January 2019 when they asked people to send superhero-, Teenage Mutant Ninja Turtles- and PAW Patrol-inspired cards and letters to the boy as he fought cancer.

Soon, packages started arriving from across the United States and countries around the world.

I cannot begin to describe what its been like getting all these cards and packages, Tracy McGregor shared last year on Facebook. Malcolm loves going to the post office to pick them up! Thank you everyone!

That support has continued throughout Malcolms ongoing treatment. Community members have contributed over $12,000 to the familys GoFundMe account, donated items to the familys Amazon Wishlist and provided meals through Meal Train.

Hundreds of people also organized, volunteered at, donated to and attended the Malcolms Marvelous Superhero Cancer Crusade fundraiser in September at Wildhorse Saloon. The event included music, childrens activities, food and basket raffles.

Malcolm McGregor, 5, his family and members of local law enforcement organizations pose for a photo after Malcolm returned to his Grand Rapids, Wisconsin, home on Sunday, Feb. 2, 2020. He has been receiving treatment in Madison for stage 4 high-risk neuroblastoma for the past four months and returned home for the first time Sunday.(Photo: Jamie Rokus/USA TODAY NETWORK-Wisconsin)

In November, two members of the Wood County Sheriffs Rescue traveled to Madison to deliver Christmas cheer and gifts to Malcolm. And many local small-business owners and individuals have held fundraisers during the past year for the family, too.

Malcolm still will have to return to Madison monthly for immunotheraphy treatment through June and by mid-summer Malcolm will be done with treatment, Tracy McGregor wrote on Facebook.

People who wish to support the family can find needed items on their Amazon Wishlist or donate money through PayPal or GoFundMe.

Read or Share this story: https://www.wisconsinrapidstribune.com/story/news/crime/2020/02/02/malcolm-mcgregor-wisconsin-rapids-who-fighting-neuroblastoma-cancer-returns-home-heros-welcome/4640466002/

Read more here:
Malcolm McGregor, 5, who is fighting cancer, returns home to hero's welcome - Wisconsin Rapids Tribune

Read More...

Pet Wearables Are a Thing Now. Meet the Company That Wants to Collect Your Dog’s Data – Inc.

February 4th, 2020 12:48 pm

Editor's note:This article is part of Inc.'s 2020 Best Industries report.

In February 2017, Donovan got lost during a trip to the park. The skittish rescue dog's ownerCollette Bunton spent hours frantically searchingbefore the rat terrier mix finally found his own way home. To make sure her beloved pet would never get lost again, Buntondid some research on tracking devices, and decided tofitDonovan's collar with a device from a San Francisco-based startup called Whistle.

Fifteen months later, Bunton received a surprise phone call from Whistle: Want to be our CEO? "You probably don't know us very well," said co-founder Ben Jacobs, the voice on the other end. Bunton, a former Roku and Logitech executive, could only laugh: "I know you, and I have ideas on what kind of things we could do."

With Bunton at the helm, Whistle has become a leader in the fast-growing pet wearables industrybyrapidly improving its technology for monitoring customers' furry friends. Its flagship product line of Whistle Go devices--think of them as doggy Fitbits with cellular data-enabled location tracking--used to simply report a pet'slocation and number of miles walked per day. Now, that data gets crunched in real time to notify you through a smartphone appwhen subtle changes, like decreased activity or increased scratching, could indicate a health problem.

"You can, today, do things that you couldn't do six months ago," Bunton says. "There really is a true technology and use case inflection point that's happening."

Whistle's devices cost between $100 and $130, plus a subscription fee. Whistle declined to disclose specific revenue figures, but says it has seen consistent double-digit revenue growth rates since its launch eight years ago.Business intelligence platforms Owler and ZoomInfo estimate Whistle's annual revenue at$30 million and $38.9 million, respectively.

Developments like longer-lasting batteries and5G technology have spedadvancesin pet wearables, according to Ross Rubin, founder andprinciple analyst at consulting firm Reticle Research. The next step, he says, will be to more heavily saturate the market with affordable products:"It's just a question of finding the right combination of cost and functionality."

The pet wearables market--which includes GPS and fitness trackers, cameras, and smart clothing--is expected to grow to $1.7 billion in 2024 from $703 million in 2019, according to data from research firm MarketsandMarkets, andWhistle estimates thatmore than a milliondevices have been sold industry-wideto date.

Striving for customization

Whistle was founded in 2012 by Jacobs, fellow ex-Bain consultantSteven Eidelman, and software engineer Kevin Lloyd. Growing up, Jacobs had a German shepherd named Bear who seemed perfectly healthy, but justdays laterhad to be put down due to intestinal twisting.The founders'idea centered not around pet tracking, but on monitoring canine activity for predictive health, which could have caught Bear's issue sooner.

The startup attracted talent from companies like Apple and Google and grew thanks to more than $20 millionin venture capital funding--until 2016, when it was acquired by Mars Petcare for $117 million. Jacobs credits Mars, Inc.--one of the largest privately owned companies in the U.S.--for allowing Whistle to continue operating independently under its new corporate umbrella.

Between 2017 and 2019, the three co-founders left the company. Eidelman and Lloyd departed for other startups, and Jacobs became head of ventures and partnerships for Kinship, Mars's pet-focused startup accelerator and $100 million venture fund. Enter Bunton, who had runRoku's devices department as asenior vice president and general manager from 2012 to 2014.Upon joining Whistle in June 2018, Bunton immediately set about shifting the company's ethos to prepare for the industry's anticipated growth.

Strategically, that involved amping up services like data collection and analysis, in addition to the company'sfocus on hardware.For example: Whistle'sPet Insight Project, in which dog owners receive the company's newest product, aWhistle Fit,for free in return for access to that device's activity, calorie burn, and mileage data. Whistle hascollected data from more than 60,000 dogs across 900-plus different breeds and mixes, which Bunton hopes will ultimately enable the app to give individualized health recommendations for every dog. "Even in my house, what my other dog, Monster, needs and what Donovan needs are different," she says.

Bunton is keenly aware of the stigma associated with data collection, and says Whistle's largely Millennial staff of about 60 employees (and eight dogs) constantly weighs in on moral and ethical considerations of issues facing the business."It's [about] getting clearer vision on the things that matter to our users," she adds."And you do that through the personal information that they're willing to share with you."

A competitive pack

Whistle says it's "fast approaching" a majority of the industry's market share by units sold. (The companydeclined to provide unitsales figures.)Still, it faces stiff competition from startups like Kansas City, Missouri-based FitBark, founded in 2013,as well as larger companies like Garmin and Motorola, which both sell pet-monitoring devices and boastfinancial heft on par with Mars.

Bunton says Whistle aims to lead the pack by focusing on personalization, offering advice tailored for individual dog owners. That could include new products, features, and significant partnerships with dog-walking and other pet-service businesseslike Rover.com and Wag. "Our biggest challenge is really one of awareness--that it's a real, usable product and not a fun gadget," Bunton says. "That's a thing that takes time, and I'm not known to be the most patient woman in the world."

Published on: Feb 4, 2020

View post:
Pet Wearables Are a Thing Now. Meet the Company That Wants to Collect Your Dog's Data - Inc.

Read More...

Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve been alerted – Endpoints News

February 4th, 2020 12:48 pm

When the tech VCs at Andreessen Horowitz entered biotech 4.5 years ago with the $200 million bio fund I, the idea was simple and hubristic: Were not going to do biotech, Vijay Pande said at the time, keeping a16zs longtime stance. Instead, the bio fund is really about funding software companies in the bio space.

In the near-half decade since, they havent softened their rhetoric. Pande and general partner Jorge Condes frequent blog posts often have the tone ofBurning Man technofuturists. Talking of a foundational shift in biology, bio-revolution, and the meaning of life, and dropping koans like what is medicine? has turned them into the well-financed New Age mystics of an AI-driven and bioengineered future.

Today, Andreessen Horowitz is launching bio fund III and putting $750 million behind it more than funds I and II combined. Theyve added new partners, as they did before fund I and II, picking up technologist and entrepreneur Julie Yoo and Vineeta Agarwala, a GV and Broad Institute alumn. Itll take much of the same tack as the earlier funds, investing early and occasionally up to Series B, and pouring funds not only into therapeutics, but also diagnostics, synthetic biology and startups bringing biological advances into other sectors, such as agriculture.

But Conde tells Endpoints News that the group has learned a thing or two since fund I. Pande had talked about extending Moores law to biology through digital therapeutics but they were wrong. It wasnt just about software and artificial intelligence. It was about the long list of ways how biology was done, how drugs were discovered and how the whole healthcare system functions. It was biotechs that worked both with machine learning and wet labs, and founders conversant in both.

Since then, theyve invested in companies like Insitro that integrate AI as a core but not sole part of a drug development chain and Asimov, which is trying to use AI and other tech systems to design a genome from scratch. They even invested in EQRx, Alexander Boriseys startup trying to use me-too drugs to change pricing.

In October, Conde, Pande and Yoo published their most soaring blog post yet: Biology is Eating the World: A Manifesto. They wrote: We are at the beginning of a new era, where biology has shifted from an empirical science to an engineering discipline.

Before the funds launch, though, Conde told Endpoints were at the end of the beginning for that era.

He talked about what theyve learned since bio I, where biology and biotech is headed and how well know when the convergence between engineering and biology hes been prophesizing has arrived.

You called this the end of the beginning for a new era. What does that mean?

Unlock this story instantly and join 71,300+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continued here:
Putting buybacks on hold, Pfizer's CEO is plotting a string of important PhII deals in the year ahead. You've been alerted - Endpoints News

Read More...

Philly teachers grapple with illness, school building conditions – WHYY

February 4th, 2020 12:48 pm

Listen to The Why wherever you get your podcasts:Apple Podcasts|Google Podcasts|Stitcher|RadioPublic|TuneIn

By Avi Wolfman-Arent

On the day before Thanksgiving in 2015, veteran biology teacher Lynn Johnson made an unusual decision she decided not to clean up her classroom.

Her students had just completed a lab experiment, which would typically send her into a frenzy of tidying and straightening. But shed felt off all day. Her body wouldnt let her clean.

My head felt kind of tipsy almost like I was drunk, Johnson said.

So instead of gathering the test tubes and beakers and thermometers, she left the space as it was frozen in a state of suspended discovery.

Then the 55-year-old flicked off the lights in Room 217 and walked out of Franklin Learning Center, the Philadelphia high school where shed taught for 16 years.

I said,`Ill just take care of that when I come back Monday, Johnson remembered. I never came back Monday.

Johnson didnt know it then, but her teaching career had just ended.

The next six months would take her on an odyssey to the edges of medicine to the brackish place where science meets mystery. She would lose her hearing, her balance and, eventually, her independence.

Those six months would flip Johnsons life, and leave her with a gnawing question:

Did my school building do this to me?

That question confronts many Philadelphia teachers now more than ever.

In September, the citys teachers union announced that one of its own 51-year-old special-education instructor Lea DiRusso had been diagnosed with mesothelioma.

Mesothelioma is caused, in virtually every known case, by exposure to asbestos a toxic mineral once commonly used in insulation and other building materials. DiRusso worked for decades in two Philadelphia schools that had asbestos inside them, making it clear there may have been a link between her illness and her job.

DiRussos diagnosis presaged a flood of media coverage on asbestos and other potentially toxic substances inside Philadelphias public schools. It spotlighted the human cost of Philadelphias crumbling school infrastructure and fanned anxiety among educators, many wondering whether their own ailments trace back to something that lurked in their classrooms.

Unlike DiRusso, though, many of them will never conclusively know if working conditions caused their illnesses. Thats because mesothelioma is rare both in its prevalence and in the definitive link it has to an environmental toxin.

Like DiRusso, Lynn Johnson worked for years in a building with a troubling environmental track record. And she, too, had to retire abruptly.

But in every other way, Johnsons story is the photo negative of DiRussos.

Her illness is so mysterious, the medical establishment wont even call it a disease. It has no known cause. It offers more questions than answers.

Johnson and so many other teachers will likely never know if any of this could have been prevented.

Johnson, now 60, was destined to teach.

The Harlem native grew up playing playing school with her identical twin sister, Leslie. Their mother taught science in New York Citys public schools. And even though the pair studied to become dentists, they both circled back to the classroom.

Lynn Johnson started as a substitute in the School District of Philadelphia in 1990. The career appealed to her because of its flexibility, allowing her time to raise her two daughters. But it quickly turned into a calling an outlet for Johnsons natural charisma and gregariousness.

I became alive when I was in that classroom, Johnson said.

In 1999, she moved to Franklin Learning Center, or FLC, a high school just north of Center City, and became a full-time biology teacher.

Johnson thrived there. She won the Lindback Distinguished Teaching Award, one of the districts highest honors, and was a finalist for Philadelphia teacher of the year.

FLC has a proud history as a prize-winning school, but its four-story building, finished in 1909, has a more dubious past.

In 1996, students walked out of FLC because of suspected exposure to lead and asbestos. School district officials promised to demolish the structure and build a new one. They even put a price tag on the project: $30 million.

Talk of a new building lingered for years. Proposals went through modifications and tweaks and wholesale changes.

I dont remember a lot of the old-timers getting excited, Johnson said. I think that as you work with the School District of Philadelphia, you lose your trust in what they say theyre gonna do because sometimes it doesnt happen.

Indeed, the new building never happened. Instead, in 2010, the district set aside money to renovate FLC. It allotted about $3 million one-tenth of the original budget for the new building.

Johnson recalls finding mysterious dust in her room when workers renovated the classroom above her. She said she remembers leaks and crumbling tile and an off-putting directive from administrators to never drink water from the schools fountains.

When she heard the school was being renovated instead of destroyed, she felt more dread than relief.

Something in my head went, Oh, Lord, they disturbing up monsters, Johnson said.

Facilities issues surfaced again at FLC in December 2019, when the school district closed the school for several days after discovering damaged asbestos in an air shaft. The district has since reopened FLC, but parents and teachers staged a rally on the first day back to protest what they see as lingering hazards inside the building.

So far this school year, the district has closed six schools temporarily after discovering exposed asbestos. District officials say theyve upgraded their protocols for finding and remediating asbestos, although the citys teachers union has questioned the districts efficacy in several instances.

When she was teaching there, Johnson knew her high school was old and in need of repairs.

Thats not uncommon. The district has itself admitted that it has billions of dollars in deferred maintenance the legacy of old buildings and insufficient funds. Johnson figured that years in a century-old school might someday harm her, but it was never an acute concern.

Its in the back of your mind, wayyyyy in the back, Johnson said.

Then in November 2015, those years of low-grade unease turned into blinking red warning lights.

After Johnson left her classroom that Wednesday before Thanksgiving, she spent much of the holiday weekend unable to lift her head from the pillow. That Sunday, she tried to attend church with her family, but midway through the service, she turned to her husband.

I cant stand, she told him. I cant hear. Take me to urgent care.

An urgent-care doctor suspected she had a bad cold and gave her Sudafed. But the symptoms didnt subside.

Over the next six months, Johnson bounced from specialist to specialist. There was an infectious-disease specialist, a rheumatologist, and a pair of ear, nose and throat doctors. One by one, they crossed off potential ailments. It wasnt a cold. It wasnt Lyme disease. It wasnt. It wasnt. It wasnt.

Meanwhile, Johnson spiraled. She resigned herself to the possibility of death.

She went totally deaf in her right ear, and lost partial hearing in her left. She lost the ability to balance without a cane. She gave up driving because her eyes seemed unable to focus whenever she turned her head.

Im stuck in this body where I cant express myself. I cant move. I cant do anything, Johnson said. I fell apart.

In spring 2016, Johnson finally got a diagnosis of sorts: Cogans syndrome.

Cogans syndrome is so uncommon and ill-defined that it is not technically a disease. Its a cluster of symptoms that the medical establishment has christened with a name because those symptoms surface in enough patients.

It helps us so that we can group patients and think about how to treat them, said Peter Merkel, an expert on Cogans syndrome and the chief of rheumatology at the University of Pennsylvania. But it does tell us that perhaps were not as precise in our understanding.

Patients with Cogans syndrome have an autoimmune disorder, meaning their own immune system is attacking healthy tissue. If that autoimmune response is taking place in a persons inner-ear while also causing vertigo and eye inflammation, doctors may suspect Cogans syndrome.

There is no test that proves a patient has Cogans syndrome.

A lot of it is patient symptoms, crude measurements, and our gestalt of whats going on, said Steven Eliades, assistant professor of otorhinolaryngology at the University of Pennsylvania. [It] can be incredibly frustrating for the patient and, quite honestly, for me.

The symptoms patients experience often subside or at least stop progressing in response to steroids. Through that treatment, along with physical therapy, people with Cogans syndrome can make modest recoveries. But the condition is chronic and has no cure.

With the help of special grip socks, Johnson can shuffle around her house in Delaware County. Longer walks require a cane or wheelchair, particularly when shes out in public, on unfamiliar terrain.

Her hearing loss is permanent, making her a frustrated bystander in social settings where she used to thrive. Once the center of a room her room Johnson now needs other people to speak slowly, directly, and facing her so she can read their lips.

Johnson gravitated to science not because of what science tells us, but because of what it cannot tell us. She loved the notion that she could reach the limits of human explanation and stare out into the unknown.

I think it connects me to my spiritual awareness, said Johnson. [Science] made me closer with God because theres so much you dont know.

Now, the unknown greets her every day in the form of an illness that the brightest medical minds struggle to understand. She struggled for years to reconcile her awe of lifes mysteries with the reality of what this mysterious ailment had done to her life.

When this disease hit, bam, I questioned everything, Johnson said.

It should be stated plainly: There is no scientific evidence linking Johnsons illness with her work at Franklin Learning Center.

In fact, there is no accepted explanation for why anyone gets Cogans syndrome. It is a sickness without a known origin.

Johnson has long suspected, however, that her work environment somehow contributed to her illness.

When FLC was temporarily closed late last year, Johnsons fears resurfaced.

She suspects a link between her school building and her illness for two main reasons.

The first is her history of allergies. Johnson had severe allergies as a child that required her to receive three shots a week, she said. Allergies are, at heart, an immune-system response to things in the environment that dont typically trigger immune responses.

From this history of allergies, Johnson has concluded that her immune system is especially vulnerable to environmental triggers, and that shes the type of person who might develop an immune-related disease after spending years in an old building with environmental hazards.

My immune system was already on high alert, said Johnson. And its been on high alert for decades.

The second reason for Johnsons suspicions is genetic. She has an identical twin sister, Leslie Childs.

Childs does not have Cogans syndrome, nor does she display the same symptoms Johnson displays.

Childs lives in New York City and has never been inside FLC. The twins both believe that Childs lack of symptoms suggest that there is something in Johnsons environment that unlocked her illness.

Its night and day between her and I physically now, said Childs. Thats the difference. Our environment was different.

None of this is conclusive.

The medical literature is far too thin on Cogans syndrome to make a judgment on Johnsons suspicions.

Cogans expert Peter Merkel said hes seen some evidence that people with the syndrome are more likely to suffer from chronic allergies. But hes also seen some evidence that the illness may be brought on by a cold or infection. This is all from years of professional observation.

Theres no proof. For Johnson, there may never be proof of her theory one way or the other.

Its difficult for patients. Its difficult for physicians to deal with uncertainty, Merkel said. But thats a lot of what we have.

So why tell a story about a teacher who worked in an old school building and has a health condition with no known link to that school building?

In part, because so many stories about Philadelphia school teachers and illness will dead-end at this same point: We simply do not know.

We know that school buildings in Philadelphia have been poorly maintained. We know some teachers will eventually get sick. In individual cases, however, we often dont know if the first and second things have any connection to each other.

Take the case of Sharon Newman Ehrlich.

The veteran science teacher worked for years at Edison High School in North Philadelphia, one of the districts newer facilities.

In 2012, she transferred to Randolph Technical High School in the East Falls neighborhood. Almost immediately, she said, her lungs rebelled.

She developed acute breathing problems that made it almost impossible for her to last through the school day. A doctor eventually diagnosed her with occupational asthma. Ehrlich suspects something in the school triggered this response. She estimated shes made 35 doctor visits over the last seven years to see if she can turn up more answers.

After wheezing through part of the 2012-13 school year, Ehrlich never taught again.

She eventually wandered down a paper trail to figure out if there was something about the buildings history that could explain her sudden reaction. What she found would alarm anybody.

Randolph, it turns out, is located inside a renovated asbestos factory. That is not a typo. A current Philadelphia high school occupies the same site and structure as a converted asbestos factory.

The factory, run by a company called Asten-Hill Manufacturing, was sold in 1968. It opened as Randolph in 1975, just seven years later.

Could any of that explain Ehrlichs health conditions? Again, its almost impossible to know.

I just want to find out whats going on with my body, she said. I want to live as long as I can, and I wanted to teach as long as I could. I loved it.

Neither the teachers union nor the School District of Philadelphia could say how many city educators take early retirement due to medical conditions. And even if that number exists, it would take significant legwork to determine how many of those retirements had even a plausible connection to environmental toxins.

The union has repeatedly raised the specter of a teacher health crisis, drawing attention to DiRussos case and making allusions to cancer clusters.

But right now, there isnt any widespread evidence that staffers in Philadelphia schools are more likely to develop serious illnesses than employees of other school districts.

Theres also the risk of over-attribution, of teachers rightfully scared by media coverage of crumbling buildings being too quick to draw a connection between their health and their schools.

Sometimes, public panic over illness and environment can have serious, real-world consequences. Several experts mentioned the perceived and unproven link between autism and vaccines as a cautionary tale. Though the medical establishment has found no tie between the two, parent suspicions have lingered for decades. And those suspicions are starting to depress vaccination rates in some places.

Thats not to say theres no tie between old buildings and teacher illness only that panic without medical proof can be a slippery slope.

After all this, Lynn Johnson is left mostly with questions and unresolved emotions.

Physically, she said, shes improved or at least adjusted. She uses FaceTime now to make calls so she can read lips. Shes more adept with her cane after going to physical therapy. And she volunteers with an organization that raises awareness about diseases similar to hers.

Still, she cant teach. And it stings.

See the original post:
Philly teachers grapple with illness, school building conditions - WHYY

Read More...

How China Is The Future of Nanoscience – OZY

February 4th, 2020 12:47 pm

Everything about Chinas drive to become a leading innovator works on a giant scale. Ambitions are enormous, budgets are vast and the focus is widespread. And in many fields, its beginning to close the gap with U.S. and European institutions. But its in the study of materials on the scale of a billionth of a meter nanoscience that China is already fast overtaking its international rivals.

From cloning to cancer research, China is using nanoscience and nanotechnology innovation to drive some of the worlds biggest breakthroughs. In July, an international team of researchers led by Chinese scientists developed a new form of synthetic, biodegradable nanoparticle. Capable of targeting, penetrating and altering cells by delivering the CRISPR/Cas9 gene-editing tool into a cell, the nanoparticle can be used in the treatment of some single-gene disorders, as well as other diseases including some forms of cancer.

In a separate project, scientists at Chinas Nanjing University haveused nanoparticles to target and destroy abnormal proteins known to causebreast cancer. Tests in mice showed the treatment reduced the size of tumors byhalf compared to the control group. At the University of Science and Technologyof China, a team of researchers claims to have given mice infrared night visionby injecting nanoparticles into their eyes.

And at the State Key Laboratory of Robotics in the northeast city of Shenyang, researchers have developed a laser that produces a tiny gas bubble. This bubble can be used as a tiny robot to manipulate and move materials on a nanoscale with microscopic precision. The technology promises new possibilities in the field of artificial tissue creation and cloning.These innovations are backed up by a scale of research thats unmatched. In 2018, Chinese researchers were on their own responsible for 40 percent of all global scientific papers in the field, with the U.S. (15 percent) a distant second.

Nanotechnology supports biomedicine and quantum technology development and makes its way into everyday life through advancements in consumer electronics and artificial intelligence, all areas where China seeks global dominance. Being at the forefront of cutting-edge nano research greatly improves Chinas prospects for success, especially in biomedicine, where it has long trailed rivals.

Drug delivery, nanomedicine and tissue engineering are rapidly growing fields that rely on our ability to engineernanoparticles and biomaterialstargeted at specific cells, such as cancer cells,to enhance the therapeutic efficacy, says Dr. Omid Kavehei, deputy director of the University of Sydney Nano Institute.

Chinas gains could help it win critical patents in advanced research in fields like cancer, where the U.S. has historically led.

Strong state support in nanoscience as in tech fields such as artificial intelligence and robotics is also a key advantage for China, Bai Chunli, president of the Chinese Academy of Sciences (CAS), conceded publicly in August. The importance the government places on competitiveness in the field is underlined by its inclusion as a strategic industry in Chinas 13th Five-Year Plan, ensuring state funding and legislative and regulatory support. Nanotech research is also a key component of the ambitious Made in China 2025 initiative aimed at turning China into a high-tech manufacturing powerhouse.

Thats allowing China to find success in myriad areas of nanotechnology. A new nanomaterial invented by CAS scientists promises to eliminate millions of metric tons of liquid pollution and emissions from organic chemicals used in printing plates and ink. It is one of the headline acts for CAS as it drives to apply nanotechnology innovation to the development of consumer tech. So far, the project has landed $780 million in investment.

China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology.

Shengfu Yang, University of Leicester

In an October 2019 paper published by science journalNano Energy, Dalian Institute of Chemical Physics announced the creation of a tiny lithium battery that is resilient to low temperatures, capable of operating at 80 percent efficiency at temperatures of -40 degrees Celsius. While the battery presents huge potential for industries from electric cars to mobile devices, the ability of the battery to operate at extreme temperatures is particularly important to the future of space technology.

Industry experts point to the return of foreign-trained Chinese researchers to the Middle Kingdom, lured by the promise of readily available funding, as an important factor of Chinas progress. The next step is for China to become self-sufficient in developing talent. Currently China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology, says Shengfu Yang, nanochemistry professor at the University of Leicester. The nanoparticle that delivers the gene-editing tool into cells was developed in partnership with scientists at Tufts University in the United States, for instance.

Enhancing innovation in the private sector will also help China kick on, says Zheng Xiao Guo, professor of chemistry and mechanical engineering at the University of Hong Kong. State-funded institutions have played a far bigger role in nanotechnology innovations, and private institutions or enterprises in this area are not as strong, he says.

But the number of private companies driving nanotech product innovation is rapidly growing, Zheng concedes. Nanopolis, the worlds largest nanotech industrial zone, located in the eastern city of Suzhou, houses several private multinationals and new Chinese startups across nanotech fields. China now also leads the globe in newly established nanotech companies. In 2018, Tencent founder Ma Huateng joined a number of high-profile businesspeople in financing the establishment ofChinas first private research institute,Westlake University, with nanotech a main focus for research.

Private-sector involvement opens new and unique pools of funding and talent, and the focus is on applicable research even in a country like China, where state-sponsored institutions still dominate, say experts.

That combination of a growing talent pool and a state-sponsored desire to become a global leader, with an expanding private-sector ecosystem, will be hard for other countries to match. Chinas big leap in small science is just starting.

Go here to see the original:
How China Is The Future of Nanoscience - OZY

Read More...

Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors – Yahoo Finance

February 4th, 2020 12:47 pm

LOS ANGELES, Feb. 4, 2020 /PRNewswire/ --Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors.To-date, the trial has accrued patients across tumor types. The expansion of the study to the US builds upon Immix' results from Australia, wherein six cohorts were dosed with no treatment-related serious adverse events observed and dose escalation is continuing.

The first US patient was dosed at Sarcoma Oncology Research Center in Santa Monica, California - led by Dr. Sant Chawla, a world renowned expert in sarcoma treatment and clinical research. Based on his extensive experience with anthracycline-based experimental therapies for sarcoma, including CytRx' Aldoxorubicin, Dr. Chawla shared his optimism for Imx-110 as an investigational candidate both from the standpoint of superior efficacy and a lower risk of cardiac complications associated with older formulations of doxorubicin.Dr. Chawla's colleague, Dr. Erlinda Gordon is the Principal Investigator leading the study at Sarcoma Oncology Research Center in Santa Monica.

Dr. Gordon is a Diplomate of the American Board of Pediatric Hematology/Oncology and previously a Tenured Associate Professor for 24 years at USC and currently a Professor Emeritus at the USC Keck School of Medicine, Los Angeles, California. She is a co-inventor of more than 150 patents in biomedical research, and patented the first targeted gene delivery system for cancer in the USA, Europe and the Philippines. She has authored more than 100 original peer-reviewed articles and served as Editor-in-Chief of the International Journal of Pediatric Hematology-Oncology, Director of the Red Cell Defects Program and the NIH-funded Comprehensive Hemophilia Center at Children's Hospital of Los Angeles and the NIH-funded Children's Oncology Group. Dr. Gordon was co-founder of two biotechnology companies and is a pioneer in the development of targeted gene therapy products.

For more information on the Imx-110 study, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03382340.

Immix also has an open call for investigator initiated studies where the company will provide Imx-110 at no charge.

About Imx-110Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.

About the CompanyImmix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix's founding investor is a family office focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit http://www.immixbio.com.

Media ContactRyan Witt+1 (888) 958-1084info@immixbio.com

View original content:http://www.prnewswire.com/news-releases/immix-doses-first-patient-in-usa-in-its-phase-1b2a-trial-in-patients-with-advanced-solid-tumors-300998208.html

SOURCE Immix Biopharma, Inc.

Read the rest here:
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - Yahoo Finance

Read More...

NanoViricides: A History Of Producing Headlines Without Producing A Product – Seeking Alpha

February 4th, 2020 12:47 pm

The Wuhan Coronavirus has rapidly become a global health crisis and is producing hourly headlines. As a result, many of the vaccine tickers started to experience parabolic reactions as investors speculate on who will benefit from the growing health crisis. NanoViricides (NNVC) is one of these tickers and has rocketed from ~$3 to around $19 per share. On January 30th, NanoViricides announced it is has already initiated a program for developing a treatment for the 2019-nCOV." In addition, the company believes that their platform technology allows them to possibly have the most rapid pathway for new drug development against viral diseases. This triggered a sharp spike in the share price and has investors keeping a close eye on NNVC for their next move. Unfortunately, the company has yet to gain support from governmental and international agencies, so it doesnt appear NanoViricides is going to be in lead considering Moderna (MRNA) at least has a clinical collaboration with NIH. What is more, the company has started several pipeline programs but has yet to put one into human trials. Consequently, I believe investors need to be cautious around this ticker and should be skeptical about its ability to be a long-term investment.

I intend to provide a brief background on the companys platform technology and pipeline programs. In addition, I discuss my concerns around the companys technology and the ability to get one of their programs through the FDA. Moreover, I recap the companys history of publicizing their intention to develop a therapy for the latest outbreak but has yet to get one of these programs into the clinic.

NanoViricides is committed to the advancement of nanomedicine drugs in the battle against viruses. The companys nanoviricide platform technology intends to develop first-in-class drugs to envelope virus particles, which should block a virus from infecting a healthy cell and will eventually destroy the virus.

Figure 1: NanoViricide Mechanism of Action (Source: NNVC)

NanoViricides has its own c-GMP capable manufacturing facility that can be used to produce their own product candidates for both clinical and commercial use. In terms of pipeline programs, the company has multiple preclinical programs that are moving closer to an IND and into human trials (Figure 2).

Figure 2: NanoViricide Pipeline (Source: NNVC)

At the moment, the company is focused on bringing their NV-HHV-101 HerpeCide program into human trials. This would be the companys lead product candidate for a topical treatment for shingles rash and would be the companys first clinical program. According to the company, NV-HHV-101 had positive GLP Safety/Toxicology and non-GLP studies. Unfortunately, the company hasnt been able to produce any animal models in order to evaluate their dermal treatment but has been using ex vivo human skin organ culture model studies to determine some safety and efficacy. NanoViricides is preparing to file an IND and transition into a clinical-stage biotech.

Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 cold sores and of HSV-2 genital ulcers programs. In addition, the company has several preclinical programs that include therapies for HIV, Dengue, Ebola, Bird Flu. These programs are at different stages of preclinical development and have demonstrated safety in animal models. According to the company, their anti-HIV drug candidate has demonstrated complete suppression of the HIV virus in mouse models, which would lead to a functional cure.

My Concerns

Does the NanoViricide entice or attack a virus? After reading through the companys presentation, I couldnt come to a conclusion about how their platform works. The company has illustrated that their NanoViricides attacks and envelopes the virus (Figure 1). However, they have also stated that the NanoViricides fools the virus that it is a host cell and then entraps the virus. Perhaps the NanoViricides work both ways, but it still has me wondering about how it is supposed to act inside the bodya human host cell is astronomically bigger than the virus that is attempting to infect it (Figure 3).

Figure 3: Size Comparisons (Source: Research Gate)

Viruses are measured in nanometers and human cells are measured in microns, yet, the NanoViricide is attempting to trick the virus to thinking it is human cell. Indeed, a virus doesnt decide to attach to a human cell because of its size but rather surface receptors. Still, I dont see it as it being tricked but rather just getting stuck and consumed...which makes me wonder about the size of a NanoViricide...How big of a virus can it cover? Can multiple NanoViricides work on one virus?

How does the NanoViricide destroy the virus? Viruses are quite resilient for just being RNA or DNA encapsulated in a protein coat. A virus requires host cells to carry out the remaining life processes in order to reproduce. This gives our bodies a chance to identify and destroy viruses with our innate and adaptive immune systems by several complex mechanisms. So, an explanation of how a NanoViricide destroys a virus needs to go beyond it encapsulates and destroys. The company explains that the NanoViricide delivers a devastating payload of active pharmaceutical ingredients API into the virus particle, thereby completely destroying the enemy. What is this API? Does it cause cytotoxicity? Is it relying opsonization? The company has a slide (Figure 4), that shows NanoVircide dismantling the capsid.

Figure 4: NanoViricide Dismantling (Source: NNVC)

Admittedly, the company is attempting to be one of the leaders in nanomedicine, so perhaps the mechanisms are beyond me and contemporary medicine. Unfortunately, we cant rely on currently approved products or science to understand how NanoViricide works, which doesnt bode well in my opinion. Contemporary vaccines, antibodies, and anti-viral drugs are effective against viruses, so I have to imagine health agencies and organizations are going to side with the standard-of-care modalities rather than take a chance with unproven technology.

Another issue I have with their technology is how they plan to run clinical trials for some of their pipeline programs. Take their shingles cream candidate, which is intended to be a topical treatment for the shingles rash. How is the company supposed to run a clinical trial for this? What would be an inclusion or exclusion trial for this? How would they know if it is better at clearing up a rash vs. placebo alone? A shingles rash appears abruptly and can last several weeks, so, determining if NanoViricides were able to shorten or diminish the impact of the rash would be difficult to measure. I have the same issue with infectious viruses, where the company is attempting to prove their NanoViricides work against a dangerous virus. With vaccines, companies are able to determine their ability to stimulate the immune system and elicit some seroprotection without the subject being infected with the virus. NanoViricides is not a vaccine, so the subject would have to be infected with the Wuhan Coronavirus in order to determine if it is effective against the virus. Overall, I see the company having a hard time clearing some of these regulatory hurdles and being able to prove its product works the way it is intended.

The other concerning issue is the companys history of developing the current global health crisis and has yet to get that program into the clinic. The company started to develop an Avian Bird Flu drug back in 2006, and yet, it has yet to hit the clinic. The same can be said for their Dengue program that was started in 2007, and the same with Ebola in 2008 and 2014. In addition, the company promoted their efforts against MERS in 2014 and has been attempting an HIV program for several years. Unfortunately, none of these programs have made it into the clinic for human trials but investors cash has made it into the companys bank account. It appears the company takes advantage of any major global health crisis by claiming they have a potential product and they are working hard to quickly progress their NanoViricides against the most recent headline virus. In reality, the company doesnt move out of discovery and preclinical studies. Sadly, investors have been enticed by the prospects of investing in a company that has an answer to the current scare, only to experience dilution that has devastated the share price over the years (Figure 5).

Figure 5: NNVC Weekly Chart (Source: Trendspider)

Even if the company wanted to push forward with development and start human trials, it will need a large amount of cash to get the ball rolling. What is more, the company would most likely need to secure commercial partners to produce and distribute their products. Admittedly, the company just raised about $7.5M in a public offering after the stock popped once the Wuhan virus started to catch the publics eye. Still, the company will most likely need some additional funding to get one of their product candidates through the FDA.

NanoViricide might be working on a potential treatment for the Wuhan Coronavirus, but investors need to be cautious here. The company has a 15-year history of promoting their attempts to develop a leading therapy for the latest virus but has yet to get one of these programs into human trials. Even if the company is able to develop a potential candidate, it is going to need the help from government agencies and institutions to be used and it looks as if some of the worlds biggest pharmaceutical and biotechs are already starting to send some of their anti-viral products to China to help with the outbreak. In fact, Johnson & Johnson (JNJ) is already working on a vaccine and has donated some of their HIV medications. What is more, NanoViricides is not even listed on a CNBC list of companies working on a Coronavirus vaccine or drug (Figure 6).

Figure 6: List of Coronavirus Companies (Source: CNBC)

Considering these points, I would advise investors to wary of investing until the company is able to get an IND and reports their first human data. Until then, I expect shorts to start piling on once the market realizes the company is reusing its old playbook of promoting a program and never following through with it.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

More:
NanoViricides: A History Of Producing Headlines Without Producing A Product - Seeking Alpha

Read More...

4 Crazy but Effective Ways to Save More Money This Year – Nasdaq

February 4th, 2020 12:46 pm

It's no secret that Americans aren't doing all that well in the savings department. An estimated 39% of U.S. adults don't have the money on hand to cover a $400 emergency, and 45% of Americans have no money earmarked for retirement savings.

If your savings efforts have been far from fruitful in recent years, it's time to do better -- even if that means going to a bit of an extreme to get there. Here are a few far-out but effective methods of boosting your savings -- and buying yourself the financial security you're currently missing.

IMAGE SOURCE: GETTY IMAGES.

If you're not familiar with no-spend periods, they involve not forking over so much as a dime on non-essentials for different periods of time. It's common to have an occasional no-spend week or no-spend month, but if you're really intent on boosting your savings, you may want to extend that restriction for a full year. That's right -- no restaurant meals, non-work clothing, or paid entertainment for an entire 12 months.

Will that be difficult? Absolutely. But imagine you currently spend $600 a month on dining out, leisure, apparel, and other items you enjoy having but can technically live without. In the course of a year, you'll be $7,200 richer.

Housing is the typical American's greatest monthly expense, so if you're able to reduce it substantially, you're apt to boost your savings in a very meaningful way. Imagine you currently rent a three-bedroom, 2000-square-foot apartment with your spouse and child for $2,000 a month. If you were to downsize to a one-bedroom (yes, you read that correctly) that takes up 800 square feet, you might reduce your rent to $1,000.

Will living in cramped quarters for a year be easy? Not at all. But if it saves you $12,000, it's a sacrifice worth making.

It costs $9,282 a year, on average, to own a vehicle, according to AAA. If you're willing to give yours up, you could wind up banking that much cash in the course of a year instead.

Now if you live in an area where public transportation is abundant, that's not such a huge ask. But if you live in suburbia, it could prove more challenging. That doesn't mean it can't be done, though. You could consider carpooling with your spouse (meaning, downsize from a two-car household to a single car), catching rides with friends or colleagues, or biking to and from work if that's a reasonable thing to do (if your office is 40 miles away, it's not).

Will giving up a car limit you logistically and socially? Probably. But think about it this way -- if it's harder to get around, you may be less inclined to dine out or spend money on entertainment, which will help your savings efforts.

The typical American spends $3,456 a year on restaurant meals and food outside the home, according to the U.S. Bureau of Labor Statistics. But restaurants generally charge a 300% markup on the items they serve, which means that if your spending is in line with the typical American's, you could save yourself close to $2,600 in the course of a year by cooking every meal you eat at home.

Will that constitute a time investment? It sure will. But you never know -- you may discover that you enjoy cooking your own food, and that doing so is healthier for you anyway.

If you're doing reasonably well financially -- meaning, you're on track for retirement and have a healthy emergency fund -- then there's certainly no need to go to any of the above extremes (unless, of course, you happen to love a good challenge). But if your near-term and long-term savings are virtually nonexistent, then you may need to take drastic measures to build them up. The good news? You don't need to commit to these extremes for a lifetime. Make any of the above moves for a single year, and your savings could easily take a turn for the much improved.

The $16,728 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. For example: one easy trick could pay you as much as$16,728 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after.Simply click here to discover how to learn more about these strategies.

The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read the original here:
4 Crazy but Effective Ways to Save More Money This Year - Nasdaq

Read More...

AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other…

February 3rd, 2020 4:45 pm

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a research collaboration with the University of California, Irvine (UCI) using AgeXs PureStem technology to derive neural stem cells, with the goal of developing cellular therapies to treat neurological disorders and diseases for which there are no cures. The collaborations initial R&D work, expected to take approximately one year, will be conducted in the UCI laboratory of Leslie Thompson, PhD, Chancellors Professor of Psychiatry & Human Behavior and Neurobiology & Behavior, a leading researcher in the field of Huntingtons disease and other neurological disorders, under a Sponsored Research Agreement handled by the Industry Sponsored Research team at UCI Beall Applied Innovation. The initial focus will be on Huntingtons disease, while other potential targets may include Parkinsons, Alzheimers, and stroke.

The primary goal of the research will be to develop a robust method of deriving neural stem cells from pluripotent stem cells in sufficient quantity and with sufficient purity and identity for use in cell-based therapy. Professor Thompsons laboratory has already accumulated safety and efficacy animal data that may support an IND submission to the FDA as early as 2021 for the commencement of clinical trials to treat Huntingtons disease.

"We look forward to utilizing AgeXs cell derivation and manufacturing PureStem technology, with its many potential advantages, including industrial scalable manufacturing, lower cost of goods, and clonal cells with high purity and identity. Our goal is to have an improved neural stem cell production method ready within a year to move into clinical development," said Professor Thompson.

"We are absolutely delighted to start this exciting collaboration with Professor Thompson, who has worked tirelessly over her career to develop a neural stem cell product candidate for Huntingtons disease and who has already generated preclinical animal data that may support the initiation of clinical studies," said Dr. Nafees Malik, Chief Operating Officer of AgeX. "Moreover, we are very excited to be entering the field of neurology, which has huge clinical and commercial potential. Neural stem cells may be very useful in other neurological disorders that are common in aging demographics, such as Parkinsons, Alzheimers and stroke."

"This is an example of the kind of collaboration we will be seeking under our newly-unveiled collaboration and licensing strategy, which is to run parallel to our in-house product development," said Dr. Greg Bailey, Chair of AgeX. "We will be collaborating with a world leader in their field on a research project which is close to the clinic."

The collaboration includes an opportunity for AgeX to organize a company to be jointly owned with Professor Thompson and other researchers to pursue clinical development and commercialization of cell therapies derived using licensed inventions arising from the research program, as well as certain patent pending technology for neural stem cell derivation, and certain technical data, including animal data, to support IND submissions.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

Story continues

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Further, in the case of AgeXs new neural stem cell program there can be no assurance that: (i) any new cell derivation methods will be invented in the sponsored research program, (ii) any derivation methods that may be developed will be sufficient to derive neural stem cells in quantities and of purity suitable for clinical use and commercialization, (iii) that any new inventions or existing technology will be licensed on commercially favorable terms, (iv) that any neural stem cells derived for therapeutic use will be shown to be safe and effective in clinical trials, and (v) that any neural stem cells derived for therapeutic use will be successfully commercialized even if clinical trials are successful. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005261/en/

Contacts

Media Contact for AgeX: Bill Douglass Gotham Communications, LLC bill@gothamcomm.com (646) 504-0890

Go here to read the rest:
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other...

Read More...

SASpine to offer Stem Cell Therapy – Yahoo Finance

February 3rd, 2020 4:44 pm

SAN ANTONIO, Feb. 3, 2020 /PRNewswire/ -- SASpine is now offering cutting edge Stem Cell Treatments to patients. For the past several years Dr. Steven Cyr, Mayo Clinic Trained Spine Surgeon, has been researching the benefits of stem cells in the treatment of multiple medical conditions including spinal disorders, specifically, conditions which involve spinal cord injury, degenerative disc disease, herniated discs, and as a supplement to enhance the success of Spinal fusions when treating instability, deformity, and fractures of the spine.

Steven J. Cyr, M.D., is a spine surgeon who has gained a reputation for surgical excellence in Texas, throughout the nation, and abroad.

Dr. Steven Cyr has been treating patients using growth factors and stem cells contained in amniotic tissue and bone marrow aspirate to provide a potential for improved success with fusion procedures, when treating herniated discs, and for arthritic or damaged joints, with remarkable success. "The goal of any medical intervention is to yield improved outcomes with the ideal result of returning a patient to normal function, when possible," states Dr Cyr. He went on to elaborate that there are times when only a structural solution can solve problems related to spinal disorders, but even in that scenario, the use of stem cells or growth factors derived from stem cell products can possibly improve the success of surgical procedures. "I have patients previously unable to jog or run return to normal function and athletic ability after injections of growth factors and stem cell products into the knee joints, hip joints, and shoulder joints," he said. "This includes high-level athletes, professional dancers, and the average weekend warrior."

There may be promise in treating patients with spinal cord injury as well. SASpine CEO, LeAnn Cyr, states, "There are reports of patients gaining significant neurological improvement after being treated with stem cells." Dr Cyr continues, "Most patients with spinal cord injuries resulting from trauma also have mechanical pressure on the nerves that result either from bone fragments or disc material compressing the spinal cord that needs to be removed along with surgical stabilization of the spinal bones. There's significant potential that stem cells bring to the equation when treating these types of patients, and I am excited about the potential that these products offer to the host of treatments to address spinal conditions and arthritic joints."

For more information about SASpine's Stem Cell Treatment Program, visit http://www.saspine.com or call (210) 487-7463 in San Antonio or (832) 919-7990 in Houston.

Related Linkswww.facebook.com/saspinewww.instagram.com/surgical.associates.in.spine

If you've been living with back pain, you're not alone. Here at SASpine, we have experienced spine specialists who are committed to improving your quality of life. (PRNewsfoto/SASpine)

View original content to download multimedia:http://www.prnewswire.com/news-releases/saspine-to-offer-stem-cell-therapy-300997355.html

SOURCE SASpine

Go here to see the original:
SASpine to offer Stem Cell Therapy - Yahoo Finance

Read More...

Dementia Live and ‘Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients’ seminars – Trumbull Times

February 3rd, 2020 4:44 pm

Published 7:30am EST, Monday, February 3, 2020

Bridges by EPOCH at Trumbull, a memory care assisted living community, located at 2415 Reservoir Ave., will host the following complimentary events in February. Call 203-935-8530 to RSVP.

Dementia Live Experience Thursday, Feb. 6, from 4 to 8 p.m. Presented by Right at Home, Caregivers are invited to reserve a time slot to step inside the body and mind of dementia. This powerful virtual experience will allow caregivers to see, hear and feel what life is like for someone living with dementia. Caregivers may bring their loved ones with memory loss to enjoy an activity with Bridges residents during this seminar. Refreshments will be served.

Caregiver Support Group Wednesday, Feb. 19, at 5:30 p.m. Caregivers are invited to trade tips, socialize with others on a similar journey and receive expert advice from dementia care professionals who understand their challenges and concerns. Dinner will be served. Caregivers may bring their loved ones with memory loss to dine with Bridges residents while they attend the group.

Dine and Discover Stem Cell Therapy for Stroke and Traumatic Brain Injury (TBI) Patients: Thursday, Feb. 20, at 5 p.m.; With Guest Speaker Dr. Peter McAllister, co-founder and Chief Medical Officer, New England Institute for Clinical Research. Stroke and traumatic brain injury strike millions of people each year. Dr. McAllister will discuss the various treatment options for the long-term effects of these conditions, including weakness, spasticity, language and cognitive difficulties and pain. He'll also discuss new research on stem cell therapy that could help restore function for stroke and TBI patients. Caregivers may bring their loved ones with memory loss to enjoy a meal and an activity with Bridges by EPOCH residents during this seminar. Dinner will be served.

See more here:
Dementia Live and 'Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients' seminars - Trumbull Times

Read More...

Freeport stem cell therapy provider Okyanos in wind-up petition battle – EyeWitness News

February 3rd, 2020 4:44 pm

NASSAU, BAHAMAS The fate of Freeports pioneering stem cell therapy provider has now become the subject of legal dispute, with its principal creditor seeking the winding-up of the company.

According to court documents seen by Eyewitness News, Okyanos claims that damagessuffered toits nearly 15,000 sq feet rented Freeport facilities as a result of Hurricane Dorian in September 2019 left thepremisesunfit for use. As a consequence, all of thecompanysbusiness ceased. That claim however has beenfiercely disputed by its landlord First Commercial Ltd who is seeking to have its dispute arbitrated and block the removal of the companys equipment which could satisfy an award in those proceedings.

Okyanos is the first licensed stem cell therapy provider in The Bahamas. It has been treating patients with chronic diseases by using their own stem cells from fat tissue. It opened to patients in October 2014, providing treatment for those with autoimmune, orthopaedic, cardiovascular and neurological conditions.

According to details outlined in a wind-up petition by its primary creditor LS Enterprise Ltd, -a companyregisteredin the British Virgin Islands, Okyanos between August 2, 2017 and May 6 2019 entered into four loanfacilityagreementsfor working capital and generalcorporate amounting to some $15.9 million. Okyanos had ultimately sought additional loans from LS Enterprise Ltd following Hurricane Dorian however was informed that it was in default of its facility agreements having ceased to carry on its business and that all loans were immediately due and payable.

According to the wind-up petition an ex parte order obtained by Okyanoss landlord First Commercial Ltd had restrained the stem cell therapy provider fromremediatingthepremisesor removing its equipment. It is claimed that substantial amounts of water and wind had penetrated the companyspremises causing major property loss and damage.Further, a lack of consistent electricity and airconditioninghad caused mold contamination.

Thecompanyattemptedtomitigateloss and damage by movingequipmentto aclimatecontrolledstorage and and preparing thecompanysoperatingfacilitiesfor moldremediation butthat was hampered by the landlord whose servants oragentsinstructed thecompanys personnel to cease anddeistfrom such activities, LS Enterprise outlined in its petition.

It further noted that in a notice to the landlord dated October 25, 2019, Okyanos had exercised its right to terminate its leaseagreementwithin 60 daysfollowingthe storm due to the facilities being unfit for use or occupancy the hurricane. On October 30, First Commercial Ltd obtained an ex parte order restraining the company from anyfurtherremediation efforts as well as the removal or disposal of equipment, LS Enterprise has claimed. The company had filed for damages with its insurance provider but had not received the majority of any such insurance proceeds the petition station.

Accordingly it is claimed that the company has insufficient funds to secure a new lease forfacilitiesto treatpatients,arbitratewith landlord torecover itsequipment and supplies, or conduct amarketingcampaignto attract patients to The Bahamas.

However, an affidavit but attorney Andre Jay Feldman, president and a member of the Board of Directors of First Commercial Centre seeking to restrain Okyanos from breaching its lease disputed the companys damages claim.

According to Mr Feldmans affidavit, a copy of which was seen by Eyewitness News, he inspected thepremiseson September 4 and beyond some minimal damage due to a single window having opened in one of theclinicalrooms, there was no damagewhatsoeverthroughoutthe clinic and nosignificantdamage referred to by the company. Mr Feldman claimed that Steve Araiza, a Houston based attorney for Okyanos had written him on September 26, 2019 seeking a rent abatement and to end theleaseon thegrounds of hurricane damage.

According to Mr Feldman, flood water had entered parts of theground flooroccupiedby CIBC and on September 15, 2019, the bank had not onlyremediatedany damage but hadreopenedfor business. He further contended that on September 4, Okyanos had allowed the Rand Memorial Hospital to use itsfacilities for urgent patient care. Mr Feldman contends that there was no damage to make the facilities unfit for use. According to Mr Feldman, since September 1 there had been no payment towards rent or electricity with respect to air-conditioning consumption. He asserted that if Okyanos is allowed to remove its assets they would be shipped out of country and would not be available to satisfy any award from arbitration. The landlord is claiming it is owed $1,768,000 and that while it plans to claim on a $890,000 loss of rentinsurancethere is no guarantee that can be recovered.

Original post:
Freeport stem cell therapy provider Okyanos in wind-up petition battle - EyeWitness News

Read More...

Stem Cell Pain Relief No Surgery Regenerative Therapy Webinar Released – Newswire

February 3rd, 2020 4:44 pm

Gilbert, Arizona based alternative medicine specialist Dr. Farid Rooh launched a new webinar on stem cell therapy, exosome injections, and other regenerative medicine therapies for chronic pain.

(Newswire.net -- February 3, 2020) -- Gilbert, AZ -- Gilbert, Arizona based alternative medicine specialist Dr. Farid Rooh launched a new webinar on stem cell therapy, exosome injections, and other regenerative medicine therapies for chronic pain.

Dr. Farid Rooh-Parvar DPSc, BCIM of Wellness 1st Integrative Medical Center in Gilbert, Arizona, announced a new webinar on the most effective regenerative medicine therapies for chronic and acute pain, arthritis, sciatica and other conditions.

More details can be found at http://bit.ly/2L8DNxY.

The newly released webinar aims to answer a series of important questions related to the most effective ways to address pain resulting form a variety of musculoskeletal conditions.

Dr. Rooh discusses the numerous applications of research-based regenerative medicine on countless patients who have seen important improvements in terms of pain relief, improved function and mobility.

The new webinar includes a detailed look at therapeutic approaches including stem cell therapy, exosome injections, amniotic tissue, adipose tissue and bone marrow therapies and more.

The focus is on helping viewers get a basic understanding on how the latest innovations in alternative, holistic and regenerative medicine can help patients suffering from a diverse range of health issues.

The webinar provides essential insights into the applications of regenerative medicine for the treatment and management of neck, back, shoulder and join pain, sciatica, arthritis, tennis elbow, loss of feeling in feet and other conditions.

All approaches are based on identifying and addressing the root cause of the patients health issues, rather than simply alleviating the symptoms.

With the latest announcement, Dr. Rooh continues to expand his range of high-quality alternative and regenerative medicine resources for patients in Arizona and beyond.

An experienced practitioner specializing in holistic and alternative medicine, Dr. Rooh offers personalized treatments for patients in Gilbert, Chandler and the surrounding areas of Arizona.

A satisfied patient said: As a new patient I was beyond impressed with this medical facility. During my consultation the kind and approachable Dr. Rooh met with me then his outstanding case manager Casi spent time with me exploring my options for a treatment plan that best suits my needs and situation. I can't express what a wonderful experience this was and I am so excited to be a new patient of theirs.

Interested parties can find more information by visiting the above-mentioned website.

See the rest here:
Stem Cell Pain Relief No Surgery Regenerative Therapy Webinar Released - Newswire

Read More...

Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies – WhaTech…

February 3rd, 2020 4:44 pm

Exosome Diagnostics Market Report analysis including industry Overview, Country Analysis, Key Trends, Key Retail Innovations, Competitive Landscape and Sector Analysis for upcoming years.

ReportsnReports added a new report on The Exosome Diagnostics Market Technologies report delivers the clean elaborated structure of the Report comprising each and every business related information of the market at a global level. The complete range of information related to the Exosome Diagnostics Market Technologies is obtained through various sources and this obtained the bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade based study regarding the Exosome Diagnostics Market Technologies.

Download a Free PDF Sample of Exosome Diagnostics Market Technologies Research Report at:

http://www.reportsnreports.com/contactme=1781607

Top Companies mentioned in this report are Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell Medicine Ltd, Tavec Inc, Codiak Biosciences Inc, Therapeutic Solutions International Inc, ArunA Biomedical Inc, Ciloa 85.

This latest report is on Exosome Diagnostics Market Technologies which explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field.

Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy.

Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intracellular transportation of genetic material to target cells.

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biological vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes.

Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

Reasons to buy this Report:

Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector, Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies, Identify trends in interventional and observational clinical trials relevant to exosomes.

Get this Report @ http://www.reportsnreports.com/purchasme=1781607

Scope of this Report:

What are the features of the exosome lifecycle?,How are therapeutic exosomes prepared?,How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?,Which companies are investing in exosome technologies?,How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Table of contents for Exosome Diagnostics Market Technologies:

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Exosomes in Healthcare 8

2.1 Overview of Exosomes 8

2.2 Drug Delivery Systems 9

2.2.1 Modified Release Drug Delivery Systems 9

2.2.2 Targeted Drug Delivery Systems 10

2.2.3 Liposomes 12

2.2.4 Viruses 14

2.2.5 Exosomes 17

2.3 The Exosome Lifecycle 18

2.4 Exosomes in Biology 18

2.5 Exosomes in Medicine 19

2.5.1 Biomarkers 19

2.5.2 Vaccines 20

2.6 Exosomes as a Therapeutic Target 20

2.7 Exosomes as Drug Delivery Vehicles 21

2.8 Therapeutic Preparation of Exosomes 21

2.8.1 Isolation and Purification 22

2.8.2 Drug Loading 22

2.8.3 Characterization 23

2.8.4 Bioengineering 23

2.8.5 Biodistribution and In Vivo Studies 23

2.8.6 Advantages of Exosome Therapies 24

2.8.7 Disadvantages of Exosome Therapies 24

2.9 Exosomes in Therapeutic Research 25

2.9.1 Exosome Gene Therapies 25

2.9.2 Exosome in Stem Cell Therapy 26

2.10 Exosomes in Oncology 27

2.10.1 Immunotherapy 27

2.10.2 Gene Therapy 28

2.10.3 Drug Delivery 29

2.10.4 Biomarkers 30

2.11 Exosomes in CNS Disease 30

2.11.1 Tackling the Blood-Brain Barrier 30

2.11.2 Exosomes in CNS Drug Delivery 31

2.11.3 Gene Therapy 32

2.12 Exosomes in Other Diseases 33

2.12.1 Cardiovascular Disease 33

2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36

3.1 Overview 36

3.2 Exosome Pipeline by Stage of Development and Molecule Type 36

3.3 Pipeline by Molecular Target 37

3.4 Pipeline by Therapy Area and Indication 38

3.5 Pipeline Product Profiles 38

3.5.1 AB-126 - ArunA Biomedical Inc. 38

3.5.2 ALX-029 and ALX-102 - Alxerion Biotech 39

3.5.3 Biologics for Autism - Stem Cell Medicine Ltd 39

3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 39

3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 39

3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 39

3.5.7 Biologics for Prostate Cancer - Cells for Cells 40

3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40

3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41

3.5.10 CIL-15001 and CIL-15002 - Ciloa 42

3.5.11 ExoPr0 - ReNeuron Group Plc 42

3.5.12 MVAX-001 - MolecuVax Inc. 43

3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44

3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 44

3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 44

3.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48

4.1 Interventional Clinical Trials 48

4.1.1 Clinical Trials by Therapy Type 48

4.1.2 Clinical Trials by Therapy Area 49

4.1.3 Clinical Trials by Stage of Development 50

4.1.4 Clinical Trials by Start Date and Status 50

4.2 Observational Clinical Trials 51

4.2.1 Clinical Trials by Therapy Type 51

4.2.2 Clinical Trials by Therapy Area 51

4.2.3 Clinical Trials by Stage of Development 52

4.2.4 Clinical Trials by Start Date and Status 53

4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67

5.1 Company Profiles 67

5.1.1 Capricor Therapeutics Inc. 67

5.1.2 Evox Therapeutics Ltd 72

5.1.3 ReNeuron Group Plc 73

5.1.4 Stem Cell Medicine Ltd 77

5.1.5 Tavec Inc. 78

5.1.6 Codiak Biosciences Inc. 80

More here:
Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies - WhaTech...

Read More...

The Neuroscience Behind Why We Feel Stressed and What to Do About It – Thrive Global

February 3rd, 2020 4:42 pm

Stress is also an emotion, one that we share with other animals and with one another across the life span, although the causes of stress can be quite variable. Chronic stress is especially harmful. Stress is also highly variablewhat would stress out one person another takes in stride, and vice versa.

Stress can have a substantial impact on longevity. Consider an experiment with Pacific salmon. After swimming upstream to spawn, and releasing tons of glucocorticoids because of the stress, they die. Its not because theyre exhausted, or for some other biologically preprogrammed reason rather, they experience rapid aging because of the production of those stress hormones. When researchers removed the adrenal glands of the salmon, which release all those glucocorticoids, the salmon didnt die after spawning.

As biologist Robert Sapolsky says,

If you catch salmon right after they spawn . . . you find they have huge adrenal glands, peptic ulcers, and kidney lesions, their immune systems have collapsed . . . [and they] have stupendously high glucocorticoid concentrations in their bloodstreams.

The bizarre thing is that this sequence . . . not only occurs in five species of salmon, but also among a dozen species of Australian marsupial mice Pacific salmon and marsupial mice are not close relatives. At least twice in evolutionary history, completely independently, two very different sets of species have come up with the identical trick: If you want to degenerate very fast, secrete a ton of glucocorticoids.

Earlier, I mentioned my University of Montreal colleague Sonia Lupien, one of the world experts on the physiology of stress. She writes:

A week seldom passes without hearing or reading about stress and its deleterious effects on health There is a great paradox in the field of stress research, and it relates to the fact that the popular definition of stress is very different from the scientific definition of stress.

In popular terms, stress is mainly defined as time pressure. We feel stressed when we do not have the time to perform the tasks we want to perform In scientific terms, stress is not equivalent to time pressure. If this were true, every individual would feel stressed when pressured by time. However, we all know people who are extremely stressed by time pressure and others who actually seek time pressure to perform adequately (so-called procrastinators). This shows that stress is a highly individual experience.

The term stress dates back to Old English in 1303 as a variant of distress and was typically used in contexts of coercion or bribery. In modern times, stress was first used by engineers in the 1850s to describe outside forces that could put a strain on a structureheat, cold, and pressure. In the 1930s, endocrinologist Hans Selye revived this use of the term to include physiological reactions to outside forces acting on the body, such as heat, cold, and injuries that lead to pain. It wasnt until the 1960s that we began to use the word the way we use it today, to mean the psychological tension we feel from anticipating adverse events, and the biological correlates of them.

You may be familiar with homeostasis, the idea that the body seeks to maintain consistency, say, in core temperature, or blood levels of oxygen.

In the last twenty years, though, weve recognized that levels of some of our physiological systemssuch as blood sugar levels, heart rate, blood pressure, and respiration raterequire continual adjustment to function optimally. This idea of stability through change is called allostasissystems fluctuating regularly in response to lifes demands.

When a situation is perceived as being stressful (because it is novel, unpredictable, uncontrollable, or painful), two major classes of stress hormones are secreted, catecholamines and glucocorticoids. They are the first hormonal systems to respond to stress. The short-term secretion of these hormones in the face of a challenge serves an adaptive purpose and leads to the fight-or-flight response (allostasis). However, the same stress hormones that are essential for survival can have damaging effects on both physical and mental health if they are secreted over a longer period of time (called allostatic load). This happens because when these primary stress hormones are increased for long periods of time, it leads to dysregulation of other major biological pathways in the body and the brain, for example, insulin, glucose, lipids, and neurotransmitters. This in turn causes a dysregulation of various other operations, such as the immune system, the digestive system, the reproductive system, cardiac health, and mental health.

Your allostatic load is the cumulative effect of stress over time; it indexes your changes in various biomarkers of stress (blood sugar, insulin, immune markers, stress markers, etc.) in response to the events of your life. Your allostatic load can be calculated by looking at levels of certain stress biomarkers, including C-reactive protein, insulin, blood pressure, and so on. Social support is a strong predictor of allostatic load, with those having less social support showing the highest load. This is another case of not knowing the direction of causalitydoes having few or no friends increase stress? Probably. Does being stressed to begin with drive friends away? Probably. Does not having friends to comfort you cause that stress to linger instead of dissipating? Again, probably.

There are many ways to reduce stress, of course. Cognitive behavioral therapy (CBT), a form of talk therapy that teaches tools to help you cope, is one of them. Exercise, meditation, listening to music, immersing yourself in nature, and sometimes just talking to friends and having social support can help to reduce stress significantly.

If emotions are constructed, like perceptions, you might think that the brain tries to fill in and predict what is going to happen next to us emotionallyand it does. For most of us, our bodies seek to maintain a kind of emotional consistency; we internally regulate our emotions so that we dont experience extremes, because they can be emotionally and physiologically overwhelming. The central nervous system learns to anticipate stressors and to make allostatic adjustments in advance. The entire process is dynamicit is an adaptable, plastic system that responds to sensory perceptions and cognitive processing by regulating neurotransmitters and hormones to either produce or recover from stress.

Part of effective regulation is the reduction of uncertainty. Our brains try to anticipate the outcome of future events, to anticipate our needs and plan how to satisfy those needs in advance. Doing this is metabolically expensive if your life is marked by great uncertainty, and the brain can easily use up its resources, resulting in a harmful increase in allostatic load. Because allostasis is a predictive system, it can be influenced or miscalibrated by early life stressors or extreme traumas. A stable fetal and early childhood environment can lead to a well-functioning allostatic system. But adverse childhood experiences can result in a system that either overreacts or just shuts down in response to what might otherwise be considered normal daily ups and downs, creating hypervigilance, reduced resilience, and sometimes wild mood swingsa lifetime in which normal allostatic regulation is never reached. Someone who has grown up in adverse conditions will have long-term memories that contain threatening and stressful information; their default prediction for even neutral events is that something bad could happen, and this kicks in their stress response, releasing cortisol and adrenaline in advance of a great many situations that are benign. On a systems level, wed say that they are not regulating their HPA (hypothalamic-pituitary-adrenal) axisthe bodys stress response system.

When we lack this kind of regulation, because either our lives are chaotic or our neurochemical systems are not properly calibrated, we can experience mood swings; we can act irrationally or impulsively, causing ourselves harm; and we can experience a range of illnesses, diseases, and other problems across the life span. Increased allostatic load (and the resulting loss of hormone regulation) can lead to cardiovascular disease, diabetes, compromised immune function, and cognitive decline. It has also been linked to a number of psychiatric conditions, for example, depression and anxiety disorders, and burnout and post-traumatic stress disorders.

Elevated cortisol levels in response to early life stress have been linked to accelerated hippocampal atrophy among both healthy individuals and people in the early stages of Alzheimers disease. Thus, successful emotion regulation may protect not only older peoples physical well-being but their mental capacities as well.

There are many factors that influence the stress response and the health of the allostatic systemits not just the obvious things like a mother who took drugs during pregnancy or an early toddlerhood surrounded by domestic violence. These factors include:

But not everyone with a stressful childhood ends up with a psychiatric disorder, or even a high allostatic load. Stressful experiences can lead to very different outcomes, depending on the interaction of the factors listed above. Some people develop resilience, grit, tenacity, and focus. Others fall apart. The prized combination that allows some people to live more positive lives, to turn lemons into lemonade, is still unknown and an active topic of research. One thing we do know is that thoughtful parenting and/ or education can put people on the more positive path and give them better overall life outcomes, reducing the disadvantages caused by childhood adversity.

Follow ushereand subscribeherefor all the latest news on how you can keep Thriving.

Stay up to date or catch-up on all our podcasts with Arianna Huffingtonhere.

See more here:
The Neuroscience Behind Why We Feel Stressed and What to Do About It - Thrive Global

Read More...

UVA Honors Its Leading Researchers at Boar’s Head Banquet – University of Virginia

February 3rd, 2020 4:41 pm

The University of Virginias top leaders gathered Wednesday evening at the Boars Head Resort to honor faculty members from across Grounds for their outstanding contributions to their fields of study and societal impact through their research and scholarly activities.

University of Virginia President Jim Ryan presented the 2019 Research Achievement Awards to 13 UVA faculty members at the dinner event.

This is the first year of the Research Achievement Awards, Vice President for Research Melur Ram Ramasubramanian said. We believe that as a university, we are what we celebrate. We want to acknowledge the talented UVA faculty who are leaders in their fields and are impacting the world in positive ways.

Provost Elizabeth Liz Magill said, Were delighted to have a chance to celebrate the accomplishments and achievements of our faculty. From education policy to precision medicine to police-community relations, there are many different fields and individuals being honored by these awards.

Im awed and immensely grateful for the contributions the award winners have made to their respective fields and to the University of Virginia, Ryan said. Our strategic plan focuses a good deal of attention on supporting research. ... Our ultimate goal is to make it possible for researchers at UVA to do their very best work.

The awards covered excellence in research, collaboration, mentorship, public impact and innovation.

Pompano arrived at UVA in 2014 and assembled a robust research team in her lab. Pursuing new technologies and new questions, she is developing new approaches to study immunity. In the areas of immunoanalysis and immunoenineering, she is working to map out cellular activity in live tissues. Her group was recently awarded a large grant from the National Institutes of Health to develop an artificial lymph node on a microfluidic chip.

Dr. Pompano chose the road less travelled by pursuing entirely new technologies and questions, rather than the safer route of building on the experiences from her Ph.D. or postdoc work, Jill Venton, chair of the Department of Chemistry, said. This strategy required spending the first 2.5 years of her professorship laying new groundwork. Dr. Pompano is a research leader in the fields of analytical chemistry and immunoengineering.

Bassoks work is in early childhood education, and her focus has been to find a way for it to both meet high standards and make a difference in the lives of young children. To do this, she has partnered with policymakers and school districts in Virginia and Louisiana to study how early childhood education opportunities can happen at scale.

In the past four years, her work has accelerated. She has published 16 articles and received more than $6 million in grant funding. In 2017, Bassok was honored with the Presidential Early Career Award for Scientists and Engineers.

Daphna Bassok has raised the bar for the field and will motivate other scholars to do more insightful and rigorous work, said Katherine Magnuson, director of the University of Wisconsins Institute for Research on Poverty.

Alhusens research focuses on improving maternal and early infant health outcomes for disabled women and women living in poverty. Her research has been funded by the National Institutes of Health, the Health Resources and Services Administration and numerous foundations, and the goal of her work is to provide higher quality care to vulnerable populations.

She has received numerous awards for her work, including the Southern Nursing Research Society Early Science Investigator Award; the Association of Womens Health, Obstetric, and Neonatal Nurses Award for Excellence in Research; and School of Nursings Faculty Research Mentor Award.

Walsh is Lockhart B. McGuire Professor of Internal Medicine and directs the School of Medicines Hematovascular Biology Center. His research is focused on clonal hematopoiesis of indeterminate potential, or CHIP.

In his lab, he is looking at how mutations in blood cells lead to chronic diseases like heart attack and stroke. Through precision medicine, he is identifying and combatting the out-of-control multiplying process in these mutations to fight age-related diseases, as well as blood cancers like leukemia.

Walsh has published more than 350 scientific articles and he is the recipient of multiple research grants from the National Institutes of Health, including a MERIT Award. In 2011, the American Heart Association designated him a Distinguished Scientist by for his contributions to cardiovascular research.

Throughout his career, Scullys research, scholarship and teaching have focused on the science of how corrosion occurs and the engineering required to prevent it. He has conducted research and collaborated with scientists around the world in numerous industries such as energy, transportation, infrastructure, aerospace, maritime and microelectronics.

His projects include two U.S. Department of Energy Energy Frontier Research centers, two Department of Defense multi-university research initiatives, as well as grants from the National Science Foundation, PPG Industries and Axalta (formerly DuPont), and the U.S. Office of the Undersecretary of Defense.

Scully, the Charles Henderson Chaired Professor and chair of the Department of Materials Science and Engineering, also co-directs the Center for Electrochemical Science and Engineering, one of the leading centers in the world focusing on materials degradation. The center has generated more than $30 million in research funding in the last 10 years and graduates on average four to five Ph.D. students per year.

Scully is technical editor in chief of CORROSION, The Journal of Science and Engineering, the premier international research journal for the field. He serves in several capacities as an ambassador for the materials-corrosion field, including several meetings to debrief the U.S. Congress on materials degradation issues of national importance.

John Scullys contributions to corrosion can be characterized by quality, quantity and longevity, said Gerald S. Frankel, Ohio State University distinguished professor in materials science and engineering and a member of CORROSIONs editorial board. It is clear that he is a world leader, if not the world leader, in metal passivity, passivity breakdown and localized corrosion, and stress corrosion cracking.

In more his more than 20 years at UVA, Lambert has advanced the science of risk analysis and systems engineering. He has led more than 60 projects related to advanced logistics systems for a total of approximately $25 million in research funding.

Lambert, a professor in the Department of Engineering Systems and Environment, has focused on the disruption of system priorities by emergent and future conditions, including technologies, regulations, markets, environments, behaviors and missions. His work has been applied to disaster resilience, energy infrastructure, coastal protection, economic development, transportation, biofuels and Olympics planning, among other challenges.

His research has been cited more than 5,000 times across more than 200 publications. In 2019, he chaired the Fifth World Congress on Risk, convening more than 300 scientists in Cape Town, South Africa.

Professor Lambert is among the most accomplished and respected scientists of systems engineering and risk analysis in the world today, said Igor Linkov, Risk and Decision Science Team Lead for the U.S. Army Engineer Research and Development Center. Lambert in his research invented the application of scenario-based preferences in risk analysis.

Connelly, Morris and Grossman worked together on a multi-disciplinary project to examine how early life experiences affect the brain and social behaviors. The team studies the brain, as well as social and cognitive development, during the first two years of life, focusing on oxytocin and its role in social behavior. Their research has helped to illuminate gaps in our knowledge about behavioral development in humans, and helps us better understand healthy and atypical development.

They received a National Science Foundation Research Award in 2017 for their cutting-edge approach in combining epigenetic, neuroscience and behavioral methods across their three labs, and their work has led to several publications.

Moore is a busy physician-scientist with his own lab, and has recently become the division chief of Pediatric Gastroenterology, Hepatology, & Nutrition at UVA. He also co-wrote the application for a Trans-University Microbiome Initiative grant, which was funded last year by the Universitys Strategic Investment Fund in an effort to make UVA a center for microbiome research. But that has not stopped him from repeatedly aiding his colleagues and providing them with key resources when they needed them.

Three colleagues joined forces to nominate Moore for the mentorship award, mentioning his critical support, his generous sponsorship and advice, and his guidance as they dealt with grant applications and the logistics of their first accepted grants. Moore went above and beyond, donating lab space and reaching out to his networks to help them make the connections and give them a leg up in their careers.

Williams only arrived at Batten two years ago, but after the violent Unite the Right rally in Charlottesville in August 2017 he was able to immediately show the value of his research and public service engagement to the University community.

Starting before he came to the University, he has spent two decades doing research in the field on police-community relations around racial profiling, community policing and the need for law enforcement officers to work with their community on issues of public safety. In all his work, he strives to make an impact on communities by building relationships and tackling problems wherever they crop up.

Dr. Williams consistently uses his knowledge, experience and passion for the good of our city, Mindy Goodall, executive director of the Charlottesville Police Foundation, said. Charlottesville is fortunate to have gained him as a citizen and champion of police and community reconciliation.

The award for Innovator of the Year was presented to Dillingham and Ingersoll for their creation of PositiveLinks, an application designed to improve health outcomes and care for people living with HIV. They will give deliver a keynote lecture Feb. 18 in the Rotunda Dome Room.

Other researchers (in alphabetical order by school) were honored for being the top 25 in sponsored funding, top cited, national award winners, named to a national academy, or named as an outstanding researcher for their school:

Timothy Beatley, PlanningBarbara Brown Wilson, PlanningMona El Khafif, Urban & Environmental Planning

Jessica Connelly, PsychologyRita F. Dove, EnglishKevin Everson, ArtTobias Grossman, PsychologyL. Ilse Cleeves, AstronomyNitya Kallivayalil, AstronomyLee M. Lockwood, EconomicsJames P. Morris, PsychologyKen Ono, MathematicsRebecca R. Pompano, ChemistryMarilyne Stains, ChemistryAlan S. Taylor, History

Christopher Barrett, Director

David G. Mick, Marketing

Derrick P. Alridge, Leadership, Foundations and PolicyDaphna Bassok, Leadership, Foundations and PolicyRobert Q. Berry, Instruction and Special EducationCatherine Bradshaw, Human ServicesBenjamin L. Castleman, Leadership, Foundations and PolicyNancy L. Deutsch, Youth-NexJason Downer, Human ServicesSara E. Rimm-Kaufman, Leadership, Foundations and PolicyWilliam J. Therrien, Instruction and Special EducationArt Weltman, KinesiologyJoanna Lee Williams, Leadership, Foundations and PolicyAmada P. Williford, Human Services

Thomas H. Barker, Biomedical EngineeringHilary Bart-Smith, Mechanical and Aerospace EngineeringCraig H. Benson, Environmental EngineeringSteven M. Bowers, Electrical and Computer EngineeringJames T. Burns, Materials ScienceBenton H. Calhoun, Electrical and Computer EngineeringJoe C. Campbell, Electrical and Computer EngineeringGeorge J. Christ, Biomedical EngineeringJason L. Forman, Center for Applied BiomechanicsJeffery W. Holmes, Biomedical EngineeringPatrick E. Hopkins, Mechanical and Aerospace EngineeringKevin A. Janes, Biomedical EngineeringJames H. Lambert, Systems and EnvironmentXiaodong (Chris) Li, Mechanical and Aerospace EngineeringPamela M. Norris, Mechanical and Aerospace EngineeringElizabeth J. Opila, Materials ScienceMatthew B. Panzer, Mechanical and Aerospace EngineeringJohn R. Scully, Materials ScienceKevin Skadron, Computer ScienceMary Lou Soffa, Computer ScienceJohn A. Stankovic, Computer ScienceMalathi Veeraraghavan, Electrical and Computer Engineering

Brian N. Williams, Public PolicyJay Shimshack, Research Dean

Jayakrishna Ambati, OphthalmologyRuth Bernheim, Public Health SciencesAlison K. Criss, Microbiology /GIDIRebecca Dillingham, Infectious DiseasesLinda R. Duska, Obstetrics/Gynecology OncologyAnindya Dutta, Biochemistry/Molecular GeneticsW. Jeff Elias, NeurosurgeryEdward H. Egelman, Biochemistry/Molecular GeneticsRobin A. Felder, Clinical PathologyEric R. Houpt, Infectious DiseasesKaren Ingersoll, Psychiatry and Neurobehavioral SciencesKaren C. Johnston, NeurologyJaideep Kapur, NeurologyAnne K. Kenworthy, Molecular Physics and BiophysicsJonathan Kipnis, NeuroscienceRobert C. Klesges, Public Health SciencesBoris P. Kovatchev, Psychiatry and Neurobehavioral SciencesThomas P. Loughran, Oncology and MedicineColeen A. McNamara, Internal and Cardiovascular MedicineWladek Minor, Molecular Physics and BiophysicsSean R. Moore, PediatricsJames P. Nataro, PediatricsImre Noth, Internal and Pulmonary MedicineMark D. Okusa, NephrologyGary K. Owens, Cardiovascular Research, Molecular Physiology and Biological PhysicsKevin A. Pelphrey, NeurologyWilliam A. Petri, Internal Medicine and Infectious DiseasesKodi S. Ravichandran, MicrobiologyPatricio E. Ray, PediatricsStephen S. Rich, Public Health SciencesLukas K. Tamm, Molecular Physics and BiophysicsGregory C. Townsend, Internal Medicine and Infectious DiseasesKenneth Walsh, Internal and Cardiovascular MedicineKatharine Hsu Wibberly, Public Health SciencesMichael C. Wiener, Molecular Physics and BiophysicsMark Yeager, Molecular Physics and BiophysicsJames C. Zimring, Pathology

Jeanne L. Alhusen, Nursing

View post:
UVA Honors Its Leading Researchers at Boar's Head Banquet - University of Virginia

Read More...

Podcast: Why do I have to get a flu shot every year? – Chemical & Engineering News

February 3rd, 2020 4:41 pm

Credit: Shutterstock

The flu virus, shown here as an illustration, evolves quickly, helping it escape our vaccines and immune systems.

Credit: Bethany Halford/C&EN

Although the Wuhan coronavirus is dominating headlines across the globe, influenza kills hundreds of thousands of people worldwide each year. In the US, millions of people roll up their sleeves annually for a flu shot. But this ritual is confusing for many. Why is it that most vaccines are effective for a lifetime while the flu vaccine is only effective for a year? And why do we sometimes get the flu even when weve gotten the vaccine? The answer is evolution: the flu is constantly evolving to evade our immune systems. In this episode of Stereo Chemistry, scientists who study flu evolution and pandemics explain what makes fighting the flu so difficult.

Subscribe to Stereo Chemistry now on Apple Podcasts, Google Podcasts, or Spotify.

The following is the script for the podcast. We have edited the interviews within for length and clarity.

StefanieOlsen: This is the info sheet from the CDC on the flu vaccine. Kind of who should get it, why you should get it, who shouldnt get it, what to expect, whats normal, whats not normal. All that sort of stuff. So Ill give you that for your perusal.

Matt Davenport: Thats Stephanie Olsen. Shes a nurse practitioner at a MinuteClinic in Cambridge, Massachusetts. Thats where C&EN senior correspondent Bethany Halford and her son went to get the flu vaccine back in the fall.

Stefanie Olsen: Are you a righty or a lefty?

Bethanys son: Im a righty.

Stefanie Olsen: OK. Cool. Well use your left arm. Find this big muscle. Here we go: clean, clean, clean. OK. One, two, three. Good job. Done. There you are.

Bethanys son: One tiny sting.

Stephanie Olsen: One tiny sting and done. Good job.

Matt: That didnt seem so bad.

Bethany Halford: It really wasnt bad at all.

Matt: Well hello there, Bethany.

Matt: Thanks so much for bringing your recorder along with you for the flu shot.

Bethany: No problem. Im actually glad I made this recording because I plan to replay it for my son every year just before we go to get our shots. Its a process thats met with no small amount of dread. But the Centers for Disease Control and Prevention recommend that most people get the flu vaccine every year.

Matt: So you and your son went in September. Its now almost February. Lets pretend youre a podcast cohost who has not gotten their flu shot. Is it too late?

Bethany: Well, CDC does recommend getting the flu vaccine by the end of October because it takes a few weeks for your body to create the antibodies that fight the virus. And this year the flu seems to be ramping up early. But doctors say that even now, its not too late to get the vaccine.

And were right in the thick of flu season. During the last flu season in the Northern Hemisphere, from October 2018 to May 2019, as many as 42.9 million people in the US got sick with the flu; 647,000 of those people were hospitalized, and 61,200 died.

Matt: Those numbers are from CDC, and theyre pretty typical for a flu season. So influenza is this huge problem, and its been that way for a long time. And its not going away, right? Unlike other vaccines, the flu shot is something you should get every year. And sometimes that flu shot isnt going to work.

Bethany: And this episode is all about how the flu outfoxes our vaccines and immune systems: through evolution. The flu virus is constantly changing itself to evade our immune systems response. And the virus changes enough each yearsometimes even enough within a single flu seasonthat the vaccine weve created is simply no longer effective.

Matt: So Beth, at the risk of sounding like a chemist right after the Nobel Prize announcement, isnt that a little more biology than chemistry?

Beth: Well, yes. But the evolutionary changes to influenza are really chemical changes. Theyre mutations in the viruss RNA that lead to amino acid changes in the viruss proteins. So there is plenty of chemistry to dig into. Were going to talk to three experts to learn how those changes happen and how studying them could help protect us better in the future. Well also look at what happens at the molecular level when a certain strain of flu becomes a pandemic that spreads quickly across the globe.

And were going to start by talking to a chemist.

Jesse Bloom: Hi, my name is Jesse Bloom.

Bethany: Jesse studies protein evolution at the Fred Hutch Cancer Research Center in Seattle. Hes also affiliated with the University of Washington and the Howard Hughes Medical Institute.

Sign up for C&EN's must-read weekly newsletter

Jesse Bloom: I actually did my PhD in chemistry, working with Frances Arnold, who studied the directed evolution of proteins.

Matt: Wait. The Frances Arnold?

Bethany: Yes, the Frances Arnold from Caltech who won a share of the 2018 Nobel Prize in Chemistry.

Jesse Bloom: After working with Frances, I remained really interested in protein evolution, but I wanted to study the evolution of proteins in a context with biomedical significance. So my lab now focuses on viral evolution, particularly the evolution of influenza virus. And the reason for that is these viruses evolve their proteins very rapidly.

Bethany: Jesse says there are really two main forms of flu evolution. One is called antigenic drift, and the other is called antigenic shift.

Matt: I like the rhyme scheme.

Bethany: Catchy, right? So lets start with the drift.

Jesse Bloom: Antigenic drift is the much more common form of flu evolution, and that essentially can be thought of as last years strain or a couple years ago strain of human flu evolving to be a little bit different, each year. Our immune systems are actually great at mounting antibody responses that protect us against flu, and theres pretty good evidence that if youre infected with a particular strain of flu, your body will provide very good, long-lasting immunity to that particular strain of flu.

Bethany: So, if our bodies provide long-lasting immunity, Im sure youre wondering why we still have to get a flu shot every year.

Bethany: Heres how Jesse explains it.

Jesse Bloom: The challenge with flu is the virus evolves very rapidly. In particular, the positions on the viral proteins that are recognized by our immune system, primarily by our antibodies, change, and they change enough that after about 5 years, many of those antibodies sort of dont work anymore. So antigenic drift and what typically is responsible for the seasonal influenza outbreaks is the virus that was present last year or the year before changing a little bit so that after about 5 years, its mostly evaded your immune systems memory.

Bethany: Now, I told you this was a chemistry story, so before we go any further, let me give you a picture of what Jesse is talking about. There are two proteins that scientists think are most important with respect to immunitywe create antibodies that bind to these two proteins in order to mount a defense against influenza. The first protein is hemagglutinin, which helps the influenza virus latch on to cells and infect them. The second is neuraminidase, which helps cleave new virus particles away from infected cells so the virus can continue to attack healthy cells. If you think of the flu virus as a sort of blob, hemagglutinin and neuraminidase stick out of that blob like pins in a pin cushion. Scientists name different strains of flu based on which types of hemagglutinin and neuraminidase they have.

Matt: Are those the proteins were referring to when we talk about like H1N1 influenza or H3N2 influenza ?

Bethany: Thats right. Right now, there are three types of flu circulating in humans: H1N1, H3N2, and influenza B.

Jesse Bloom: I mean, they all evolve pretty fast, like, compared to almost anything else we encounter in life. But definitely H3N2 evolves the fastest. H1N1 is sort of in the middle. And influenza B is the slowest, although influenza B is still pretty fast. And this plays outfor instance, influenza B is most known for infecting children because its relatively less good at escaping immunity. Obviously children dont have any immunity at all, if they havent been vaccinated, anyway, to escape. So theyre always going to be susceptible. And then H3N2 is sort of best at infecting older peopleits also good at infecting younger people, but its good at affecting all agesand probably the reason is that H3N2 is evolving the fastest. So it can best get away from that prior immunity.

Matt: So, when he says something is evolving fast, what does that mean on a molecular level?

Bethany: Take H3N2 influenza, for example. The hemagglutinin protein on H3N2 will change three to four of its amino acids every yearan evolution rate that Jesse says is extraordinarily high.

Matt: OK, so I understand why these gradual changesthe antigenic driftmake it so that we have to get the flu vaccine every year. But why dont we need frequent vaccinations for all RNA viruses? Like measles?

Bethany: CDC recommends just two shots for measles as part of whats called the MMR vaccine. It protects you from measles, mumps, and rubella. You get the first shot when youre about a year old, the other when youre about 5 years old. It seems that the parts of the measles virus that the immune system goes afteror makes antibodies forjust dont seem to be changing that much. We know this because before the measles vaccine existed, people who got measles only got it once in their lifetime. And in the 50 or so years since weve had the vaccine, people who get it dont get measles. As Jesse explains, theres no reason measles cant drift like the flu, thats just not what we see. So the thinking is that measles is mutating, but not in a way that helps the virus. Its not as wily as influenza.

Matt: That is super interesting. But . . .

Bethany: How does knowing this help fight the flu?

Bethany (in interview): Can you talk a little bit about how studying flus evolution can help us fight the virus?

Jesse Bloom: So first, the way the flu vaccines are made currently, theres sort of this forecasting problem. We know that the vaccine works better when the vaccine is more similar to the virus that is infecting people. But it takes a while, maybe about 9 months, to really produce enough vaccine to be given to everybody. And because the virus is changing a little bit every year, you have to predict what virus is going to be circulating 9 months in the future. So you basically have to say, How do we think the virus is going to be evolving? And so by understanding the viruss evolution, we can make better decisions about which flu strain should go in the flu vaccine. And when those decisions are better, the vaccine will work better.

Bethany (in studio): Jesse also says that studying evolution helps scientists understand which parts of the flu virus change the least or mutate less frequently. It could be that some of these less-dynamic parts of the flu could become targets for longer-lasting vaccines.

Matt: I can dig it. So whats driving the evolution? Whats making the proteins change?

Bethany: Good question. Lets get another influenza evolution expert to chime in.

Adam Lauring: So Im Adam Lauring. Im an associate professor here at the University of Michigan. I am a physician-scientist, which means I spend part of my time actually doing clinical work in infectious diseases. But most of my time I spend actually running a research lab, in which we study virus evolution, including influenza virus. Evolution is really for me kind of the be all, end all in the problem of influenza. Evolution has immediate and real-world impacts.

Bethany (in interview): When we say flu is evolving, what is actually going on?

Adam Lauring: At its simplest, the flu will mutate, and that means that its making changes in its genome which will lead to changes in its proteins, and those protein changes will make the virus different. And then theres selection. And so viruses that are better at doing what viruses do will take over, and the viruses that are less fit will die away. And so its kind of like you learned when you first learned biology: its survival of the fittest, or the best one wins. And so the virus is mutating all the time, and the ones who are best able to make copies of themselves and spread from person to person are going to become the new viruses and replace the old ones.

Bethany (in studio): Now, flu evolution is a complex process thats influenced by many things. But one thing that helps flu evolve especially fast is that its an RNA virus. That means its genes are stored in ribonucleic acid, or RNA. RNA viruses, in general, evolve faster than viruses that store their genetic information in DNA. Both DNA and RNA viruses have proteins called polymerases, and the job of these proteins is to make copies of the viruss genetic code. DNA polymerases, however, have a built-in proofreading function. They can check their work for mistakes and correct them. RNA polymerases dont do that.

Adam Lauring: Because of this, most RNA viruses have mutation rates or error rates that are about a thousandfold higher than for DNA viruses. That means that an RNA virus can generate mutants way more quickly, and then some of those mutants will confer an advantage to the virus, and that will lead to faster evolution.

Bethany: Adam says that all of the flu viruss proteins can and are evolving but that mutations to the hemagglutinin and neuraminidase proteinsthe Hs and Nsare the ones that matter most.

Adam Lauring: Mutations in those proteins tend to make a bigger difference in terms of whether the virus succeeds or fails, and a major reason is those proteins, theyre on the surface of the virus, and so theyre targeted by the immune system. And so you have antibodies targeting those proteins. So if a virus figures out a way to escape those antibodies, it will do better than its brothers and sisters.

Bethany: So weve been talking a lot about mutation, but Adam also points out that theres a lot more to evolving quickly than just how fast a virus mutates. For instance, the number of people infected could play a role. The example he gave me is the more people infected, the more opportunities the virus has to evolve. Thats because a greater diversity of people would mean a wider variety of immune systems, and the virus would need to generate new or different versions of itself to survive.

Adam Lauring: Broad strokes, flu does evolve quickly but maybe not for the reasons we typically think. And there are probably subtleties yet to be uncovered.

Bethany: To try to uncover some of those subtleties, Adams lab has been collaborating with Arnold Monto and Emily Martin, who are epidemiologists at the University of Michigan School of Public Health. For about 8 years, they have been following 300 or so Michigan families to see what viruses are circulating among them and how their immunity changes over time. The flu virus is part of this sampling. As part of the work, they collect nose and throat swabs anytime someone from one of those families gets sick.

Matt: Oh, wait. Everyone gets swabbed when anyone gets sick?

Bethany: Right. Heres why.

Adam Lauring: Its really kind of a slice of what flu is doing locally, and youre not really biased by only getting sick people or people who tend to go to the doctor.

Bethany: Adams group realized that the collection of samples the epidemiologists had accumulated gave them a great opportunity to see how flu viruses were evolving outside of a laboratory. So they raided the freezer and then did in-depth genetic sequencing of all the influenza viruses they found.

Adam Lauring: The virus makes a lot of mutations. Everybodys flu viruses, their population is actually a little bit different. So I could have the flu and you could have the flu and wed be in the same room, but our flu viruses might be a little bit different if you really looked hard enough. And so what were able to do with our sequencing is really understand those subtle differences in kind of the overall flu mixture that each person has in them.

Bethany: And then they compare, see which versions are actually being transmitted from person to person.

Adam Lauring: And that is really important in understanding evolution, right, because you may generate all sorts of cool viruses inside you. But if they dont make it onto the next person, its kind of a dead end. And that virus could be the most awesome virus there is, but if it doesnt get transmitted, its gone forever. And so what we tried to do is understand exactly how many viruses kind of go across from one person to the next. And we found that its actually a really small number. Its hard for a new virus to kind of make it both within a host and to get on to the next host.

Matt: Thats wild. So, if its hard for a new flu virus to survive within a host and also hard for that virus to make it to the next host, how is that much evolution happening? Why do we still need to get the flu vaccine every year?

Bethany: Adam says its really just a numbers game. Hundreds of millions of people are infected with the flu each year, which gives the virus lots of opportunities to make a successful mutant.

Adam Lauring: One analogy I give is flu viruses are sort of like people playing the slot machines. And so most of the time the virus is losing when you talk about kind of on an individual host or in a household. But if you have a hundred million people playing the slot machines, youre going to hit the jackpot with some frequency.

Matt: I like that analogy. Its kind of empowering. Like humanitys the house and the flus a rube giving us their money.

Bethany: Sure. Just remember, the flus currency isnt money. Its trying to survive, and when it thrives, it makes you sick. So its not like a casino catches fire whenever someone hits the jackpot. And the analogy really works best for antigenic drift. Weve got a whole other type of evolution to talk aboutremember how I said there were two? This second kind leads to pandemics, and well talk about it . . . after the break.

Matt: Hey. Sorry to leave you hanging like that, but dont worry. Theres going to be a silver lining. Were not just going to be like. The flu. Yeah, its brutal. Welp, see you later.

Thats the great thing about covering chemistry. Its that were not just talking about problems, were talking to the people solving them.

In fact, earlier this month, Leigh Krietsch Boerner wrote a phenomenal piece for C&EN about how researchers are examining the effectiveness of flu shots, especially vaccines made using eggs.

Weve got a link to Leighs story in the description, but if you want to inoculate yourself against the possibility of missing more of our great coverage, sign up for our newsletter. Well send a weekly dose of chemistrys biggest goings-on right to your inbox. Head to cenm.ag/newsletter to subscribe.

Matt: So, Bethany, you said there were two main forms of influenza evolution: antigenic drift, which weve been talking about. But there was also, what was that rhyme again?

Bethany: Antigenic shift.

Matt: Right, antigenic shift. Whats that?

Bethany: When the influenza virus undergoes antigenic shift, it experiences a much larger change. It changes so much, in fact, that we usually dont have much of an antibody arsenal built up to fight it.

Matt: And how does it make such a dramatic shift?

Bethany: So, antigenic shift can happen a few different ways. Another way flu is different from measles is that flu doesnt just circulate in people. It also circulates in many other animal species, like pigs and whales and birds.

Bethany: Yeah. But it turns out, the vast majority of influenza strains that exist in the world actually are circulating in wild waterfowl. And sometimes those viruses will jump from birds to people or from birds to pigs to people, for example.

A single animal can also get infected by two different strains of flu from two other animals. Those viruses then swap some of their genetic material to make a new, third strain.

However its happening, when the flu is evolving outside of humans, vaccine makers and our immune systems are largely blind to what these viruses look like. That means if one of these viruses does jump to humans, it could hit us hard. Were talking global pandemic here. Thats because the virus would look very different from anything our immune systems have seen, and we might have little or no ability to recognize the strain or fight it.

Matt: That sounds gnarly. And a little scary.

Bethany: It is. Global flu pandemics occur when a novel influenza virus spreads quickly around the globe.

Matt: Is that why were so concerned when people get infected with flu on chicken farms, for example?

Bethany: Yes. And you may have heard about the recent outbreak that started in Wuhan, China. Thats a coronavirusso, not the flubut its another example of a pathogen that made the jump into people from animals. But theres actually a lot more to becoming a global pandemic than just generating a virus people havent seen before. Lets talk to someone who studies how global influenza pandemics emerge.

Seema Lakdawala: My name is Seema Lakdawala. I am an assistant professor at the University of Pittsburgh in the School of Medicine and the Department of Microbiology and Molecular Genetics.

Bethany: Seema says there are several hurdles a new virus has to overcome before it can become a pandemic

Seema Lakdawala: And the first hurdle is that they have to be able to infect the human host. And so its hard for some viruses that may be emerging in birds to infect the human hosts unless theres access. And so it doesnt happen as readily, but that does happen in many occasions.

Matt: That makes sense, right? Its kind of like what Adam was talking about earlier. How you can have all these cool bugs being made in humans, but if they cant survive, and if they cant make the leap in humans, they really arent a threat.

Bethany: Right. And Seema says the next hurdle, after a virus has made it into a human, is the virus being able to survive in respiratory systems. In humans, the flu is a respiratory infection, but in birds, its gastrointestinal. Influenza virus can move from birds to people through contact with feces or other secretions, butdont worrynot from eating poultry or eggs.

Read more from the original source:
Podcast: Why do I have to get a flu shot every year? - Chemical & Engineering News

Read More...

Colombia’s first ever science minister faces calls to resign over fungi-based cancer treatment – Science Magazine

February 3rd, 2020 4:41 pm

Mabel Gisela Torres Torres, Colombias new minister of science, is under fire for giving cancer patients a fungi extract.

By Rodrigo Prez Ortega Feb. 3, 2020 , 4:33 PM

In December 2019, when Colombian President Ivn Duque Mrquez appointed molecular biologist Mabel Gisela Torres Torres to be the first head of the newly created Ministry of Science, Technology and Innovation, only a few of the nations researchers knew who she was.

Torres was a total stranger, recalls Gustavo Quintero Hernndez, dean of the School of Medicine and Health Sciences at Del Rosario University.

Now, Torres is obscure no moreand finds herself at the center of controversy that has included calls for her resignation.

The storm began on 10 January, 1 day before Torres took office, when the newspaper El Espectador published a story raising questions about her research record. The story reported a claim Torres made, during a broadcast interview in August 2019, that she had essentially run an informal, uncontrolled clinical trial with cancer patients. Torres said she had given a brew made from a fungus she was studying to patients with cervical, breast, and brain cancer, and that their health had improved. She didnt seek formal ethical, safety, and efficacy reviews prior to starting the work because it would have taken too long, and because she believed the fungus posed no threat to human health, she told the same paper the next day. She also said she hasnt published the extensive data she has claimed to collect from such studies as an act of rebellion, although she plans to submit an application to patent her findings.

Torress remarks drew immediate condemnation from many Colombian scientists, with more than six scientific and medical societies issuing statements of concern. We cannot accept derogatory attitudes in relation to the scientific method, the laxity with ethical codes of scientific experimentation, and of disdain for the process of publication and peer review, said the Colombian Academy of Exact, Physical and Natural Sciences in a statement.

We can only regret that the course of how to do science in our country has been left in the hands of pseudoscience, said the Colombian Association of Medical Faculties (ASCOFAME) in a statement.

Some researchers believe Torres should step down. We want her to resign, says Juan Manuel Anaya, an immunologist at Del Rosario University. Her act of offering a hope for patients with cancer has to be criticized, he says, because it was unethical and eventually dangerous.

Torres did not respond to requests for comment from ScienceInsider. But on 30 January she told the newspaper El Tiempo that she would not resign. I have always believed that [being appointed minister] is no accident, she said.

In an earlier statement, Torres defended her work, which focused on the taxonomy, genetics, and bioactive compounds of fungi in the genus Ganoderma. At no time have I stated in a simplistic way that this species is the cure against cancer, she wrote in the 18 January statement. I have not offered a medicine, let alone commercialized it. I have rigorously observed the ethics protocols established for scientific experimentation in general and those that apply specifically in my disciplinary field.

The controversy had disheartened many researchers who just 1 year ago were celebrating a successful push to create Colombias first science ministry. It has been very frustrating. We hoped that we get started on the right foot, says Lucy Gabriela Delgado Murcia, an immunologistat the National University of Colombia, Bogot. She was part of the Misin Internacional de Sabios, an advisory group of 47 members of the national and international scientific community that helped set goals for the new ministry.

Its very astonishing that a person who has difficulty [adhering to] the scientific method is the person that will lead the science of this country, says physician Quintero Hernndez, president of the board of ASCOFAME.

Others are withholding judgment. Laura Guzmn Dvalos, who was Torress Ph.D. adviser at the University of Guadalajara, described Torres as a brilliant student and notes that studies have suggested metabolites in the fungi Torres studied have shown potential as a cancer treatment in cell and mouse studies. And she says that although she is not aware of any clinical studies in humans, I dont think its a bad idea that Torres gave her fungi brew to patients. The fungi is meant to complement, not replace, traditional cancer treatments such as chemotherapy, she notes. She herself takes a supplement derived from fungi, Dvalos says, and many professors at her university give the supplements to cancer patients.

Marine biologist Juan Armando Snchez Muoz of the University of Los Andes, who was also a member of the Misin Internacional de Sabios, says he wishes Torres would be more emphatic on her comments on the scientific method and medical ethics. But he also notes that, in her current position, her job isnt to do science but to administrate research programs and funding. We have to give her chance to demonstrate that she can do it, he says.

Excerpt from:
Colombia's first ever science minister faces calls to resign over fungi-based cancer treatment - Science Magazine

Read More...

Study likens Earth’s evolution to creation of Frankenstein’s monster – Harvard Gazette

February 3rd, 2020 4:41 pm

Modern biology relies on relatively homogeneous building blocks to encode genetic information, said Seohyun Kim, a postdoctoral researcher in chemistry and first author on the paper. If Szostak and Kim are right and Frankenstein molecules came first, why did they evolve to homogeneous RNA?

Kim put them to the test, pitting potential primordial hybrids against modern RNA and manually copying the chimeras to imitate the process of RNA replication. Pure RNA, he found, is more efficient, more precise, and faster than its heterogeneous counterparts. In another surprising discovery, Kimfound that the chimeric oligonucleotides like ANA and DNA could have helped RNA evolve the ability to copy itself. Intriguingly, he said, some of these variant ribonucleotides have been shown to be compatible with or even beneficial for the copying of RNA templates.

If the more efficient early version of RNA reproduced faster than its hybrid counterparts, it would, over time, out-populate its competitors. Thats what the Szostak team theorizes happened in the primordial soup: Hybrids grew into modern RNA and DNA, which then outpaced their ancestors and, eventually, took over.

No primordial pool of pure building blocks was needed, Szostak said. The intrinsic chemistry of RNA copying would result, over time, in the synthesis of increasingly homogeneous bits of RNA. The reason for this, as Seohyun has so clearly shown, is that when different kinds of nucleotides compete for the copying of a template strand, it is the RNA nucleotides that always win, and it is RNA that gets synthesized, not any of the related kinds of nucleic acids.

So far, the team has tested only a fraction of the possible variant nucleotides available on early Earth. So, like those first bits of messy RNA, their work has just begun.

Read the rest here:
Study likens Earth's evolution to creation of Frankenstein's monster - Harvard Gazette

Read More...

Academia Gets The First Production Cray Shasta Supercomputer – The Next Platform

February 3rd, 2020 4:41 pm

Indiana University is the proud owner of the first operational Cray Shasta supercomputer on the planet. The $9.6 million system, known as Big Red 200 to commemorate the universitys 200th anniversary and its school colors, was designed to support both conventional HPC as well as AI workloads. The machine will also distinguish itself in another important way, being one of the worlds first supercomputers to employ Nvidias next-generation GPUs.

We will get to that in a moment.

Although Big Red 200 is the first Shasta system to be up and running, it is one in a pretty long line of machines that Cray, now a unit of Hewlett Packard Enterprise, hopes to deploy in the coming decade based on this architecture. Notably, Shasta was tapped by the Department of Energy to be the basis of its first three exascale systems. Later this year, Berkeley Lab will be the recipient of a pre-exascale Shasta system, in this case, the NERSC-9 machine, code-named Perlmutter. Big Red 200 will have just a fraction of the capacity of those super-sized systems, but the use of Nvidias upcoming GPUs will make it a unique resource for anyone with access to the machine.

Those GPUs are expected to be plugged into Big Red 200 later this summer that according to Brad Wheeler, vice president for information technology and chief information officer. The exact nature of those GPUs is unknown, which is understandable, inasmuch as Nvidia has not announced they are even on the way. The most likely explanation is that they will be the next-generation Tesla GPUs based on the upcoming Ampere architecture.

Our best guess is that Ampere GPUs will be unveiled in March at Nvidias GPU Technology Conference, which suggests they will be ready to ship in time for their summer rendezvous at IU. Note the Berkeley Labs Perlmutter system is also in line for these next-generation Nvidia chips in the same general timeframe as the Big Red 200 upgrade.

According to Wheeler, the addition of the new GPUs was something of a fluke. The original plan was to outfit the system with Nvidia V100 GPUs, which would have brought its peak performance to around 5.9 petaflops. But as they were getting ready to receive the system, an opportunity presented itself to wait a bit longer and move up to Nvidias newer technology. At the last minute, we decided to take the machine in two phases, explained Wheeler.

The first phase of the system the one currently up and running at IU is comprised of 672 dual-socket nodes powered exclusively by CPUs, in this case, Rome Epyc 7742 processors from AMD. (Yes, AMD ate Intels lunch yet again in another high-profile HPC deal). The second phase of the new IU supercomputer will commence this summer and will bring additional AMD Rome nodes online and these will be equipped with one or more of the next-generation Nvidia GPUs. When all is said and done, Big Red 200 is expected to deliver close to 8 petaflops.

As a result of the two-phase approach, waiting a few more months yielded an additional two petaflops of performance, even though, according to Wheeler, they ended up buying a smaller number of GPUs. (The newer silicon is expected to deliver 70 percent to 75 percent more performance than that of the current generation.) Perhaps more importantly, having the latest and greatest GPUs will help attract additional research dollars to the university, especially for AI-enabled research.

Speaking of which: The university is particularly interested in pointing out the artificial intelligence capabilities of the new machine, claiming that it will be the fastest university-owned AI supercomputer. Of course, until the new GPUs are unveiled, we wont really know the extent of those capabilities, but they are almost sure to be more impressive than that of the current V100, which is certainly no slouch in that regard. Although, Big Red 200 is expected to deliver about eight times the peak performance of its predecessor, Big Red 2, Wheeler told us that for AI work, it will be a far bigger jump.

That is because Big Red 2, which was installed in 2013, was equipped with the now-ancient Kepler Tesla K20 GPU accelerators. That processor topped out at 1.18 FP64 teraflops and 3.52 FP32 teraflops. It had no specialized logic for machine learning, such as the Tensor Cores employed in the current Volta GPUs, or even FP16 capability, as is coming to many different compute engines in both the raw and bfloat16 flavor invented by Google and increasingly in favor. Big Red 2 was dismantled in December 2019 to make room for its successor, after having served IU researchers for seven years.

The new GPUs are certain to get a workout at IU. Researchers there are already applying AI techniques in areas like medical research and molecular genetics, cybersecurity, fraud prevention, and neuroscience, to name a few. Of course, the new system will also be expected to support more conventional HPC workloads, including the usual suspects such as climate modeling, genomic analysis, and particle physics simulations. Depending on the code employed, the GPUs could come in handy in these domains as well. There were so many things being done algorithmically to really start to enable GPU use across a range of research disciplines and methods, notes Wheeler.

To make up for the slight delay in GPU deployment, the university is upgrading its Carbonate cluster with 96 additional Tesla V100 accelerators. It was previously outfitted with 16 P100 GPUs and 8 V100 GPUs according to the systems webpage, and was the main resource for IU researchers that needed modern AI hardware. The additional V100s will provide some extra capacity until phase two of Big Red 200 comes online.

Featuring highlights, analysis, and stories from the week directly from us to your inbox with nothing in between.

Subscribe now

See more here:
Academia Gets The First Production Cray Shasta Supercomputer - The Next Platform

Read More...

Page 697«..1020..696697698699..710720..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick